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SUMMARY 
 
Distal myopathies are hereditary disorders that cause progressive distal muscle 
weakness and atrophy without clinically significant involvement of proximal 
muscles at the early stages of the disease. One representative of this group is 
autosomal dominant tibial muscular dystrophy (TMD). TMD was originally 
described in Finland and the disease prevalence according to the known patients 
is currently 7:105. The first symptoms, weakness of ankle dorsiflexion and 
inability to walk on the heels, occur after 35 years of age. Tibialis anterior 
muscles are particularly involved and muscle weakness and atrophy usually 
remain confined to the anterior compartment of the lower legs. The objective of 
this study was to clarify the molecular genetic background of TMD. 
 
The TMD locus was assigned to chromosome 2q31 by performing a genome 
wide scan and linkage analysis on one Finnish family. The locus finding was 
confirmed in three other families. Haplotype analysis revealed a founder 
haplotype shared by TMD chromosomes of the affected individuals. The critical 
region was restricted to approximately one cM spanning the region between 
markers D2S2173 and D2S2310. Genetic homogeneity of TMD was supported 
by linkage to the 2q31 locus in a French family. Further, late-onset distal 
myopathy (LODM) with phenotypic resemblance was also linked to 
chromosome 2q31. 
 
The critical region included one major candidate gene encoding the giant 
sarcomeric protein titin. Sequencing of the gene identified TMD causing 
mutations in the 363rd and the last exon (Mex6), which encodes an Ig-domain 
located in the M-line region of the sarcomere. The identified mutations were an 
11-bp deletion/insertion changing four amino acids in Finnish patients and a 
leucine to proline change in French patients. The alterations possibly disrupt the 
Ig-domain structure. Three Finnish patients with severe limb-girdle muscular 
dystrophy phenotype were homozygous for the 11-bp mutation. 
 
Muscle biopsy of a homozygous patient showed specific loss of antibody 
recognition of the carboxy-terminal titin epitopes located in the M-line, while 
the sarcomere structure remains intact. Further, the mutated Ig-domain resides in 
the vicinity of the calpain 3 binding site. Mutations in calpain 3 cause 
LGMD2A. The amount of calpain 3 varied in the muscle samples from 
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heterozygous TMD patients and there was a severe loss of calpain 3 in the 
muscle of the homozygous patient. Myonuclear apoptosis and perturbation of 
the IκBα/NF-κB pathway similar to LGMD2A were observed in both 
heterozygous and homozygous patients. Identification of the TMD causing 
mutations in titin and the preliminary results of the consequences are the basis 
for future studies on molecular mechanisms involved in the muscle degeneration 
in TMD and other myopathies. 
 
During the TMD study, a new phenotype of autosomal dominant distal 
myopathy was discovered in a Finnish family and the aims of this thesis became 
broader to include the characterization of this phenotype. The first symptoms are 
clumsiness with the hands and stumbling around the age of 30. The thenar and 
hypothenar muscles of the palms are involved at onset. The disease progresses 
to other hand muscles, to the lower legs, the forearm muscles, and later to the 
proximal muscles. This phenotype is distinct from the previously described ones 
and was termed MPD3. Molecular genetic studies were initiated. Unexpectedly, 
a genome wide scan provided significant evidence for linkage to two 
chromosomal regions, 8p22-q11 and 12q13-q22. Statistical and haplotype 
analyses showed identical results for both loci making any distinction 
impossible. In the future, both loci may be tested with unclassified distal 
myopathy patients and with families reported by others to confirm the locus 
assignment. 
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REVIEW OF THE LITERATURE 
 
Introduction 
 
During the preceding two decades, there has been immense progress in resolving 
the molecular genetic background of the inherited muscular dystrophies and 
myopathies. Most of the classified entities have been assigned to a chromosomal 
locus or the causative gene and mutations are known. This has resulted in 
reclassification of these disorders based on molecular genetics. Pathogenetic 
mechanisms and details of the muscle cell structure and function have been 
studied both at the molecular and cellular level. However, many questions 
remain to be answered. One of the most intriguing is the molecular background 
of the selective pattern of muscle involvement in the different muscular 
dystrophies and myopathies. 
 
Distal myopathies  
 
Classification 
 
Distal myopathies are hereditary disorders that cause progressive distal muscle 
weakness and atrophy without clinically significant involvement of proximal 
muscles at the early stages of the disease. Serum CK activity ranges from 
normal or slightly elevated levels up to 150 times the upper normal limit in 
certain types of distal myopathy. Electrophysiological findings are compatible 
with myopathy without myotonic discharges or altered nerve conduction 
velocities. Morphological studies of muscle tissue show myopathic changes: 
variation in fibre size, central nuclei and increased connective tissue are seen in 
muscle biopsy. Fibre necrosis and regeneration are a less frequent findings in 
most entities. At later stages, the muscle tissue may be totally replaced by fat 
and fibrous connective tissue. There are no inflammatory cell infiltrates. 
Rimmed vacuolated fibres are often present in the biopsy but are not a specific 
finding for distal myopathy. Central cores, nemaline bodies, inclusion bodies, 
desmin storage and accumulation of glycogen or lipid are associated with other 
diagnoses, although the clinical presentation may show a distal phenotype. 
(Barohn 1993, Somer 1995, Somer 1997, Barohn et al. 1998). 
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During the early nineties four clinical entities were proposed for classification of 
the adult onset distal myopathies, two autosomal dominant  and two autosomal 
recessive disorders: late adult onset myopathy with onset in the hands (Welander 
distal myopathy) and late adult onset myopathy with onset in the legs (Late-
onset distal myopathy, tibial muscular dystrophy), early adult onset myopathy in 
the posterior compartment of the lower legs (Miyoshi myopathy) and early adult 
onset myopathy in the anterior compartment of the lower legs (Nonaka 
myopathy) (Barohn 1993). Because the morphological findings in many distal 
myopathies have similarities to those found in sporadic inclusion body myositis 
(s-IBM), the term hereditary inclusion body myopathy (h-IBM) has also been 
used for its classification (Askanas and Engel 1995, Griggs et al. 1995).  
 
With the identification of the molecular genetic cause for the different distal 
myopathies, the classification suggested by Barohn (1993) has become obsolete 
and progress in molecular studies has set a completely new approach for the 
diagnostics. However, the genotype-phenotype correlation may not be 
straightforward. Many known genes responsible for distal myopathies may also 
cause proximal phenotypes or cardiomyopathy making the category of distal 
myopathies somewhat arbitrary. Nevertheless, the term distal myopathy is still 
useful for clinical practise when the causative mutation is not known. (Udd and 
Griggs 2001). Classification of the distal myopathy entities is reviewed in table 
1. In addition, there are several muscle diseases that present distal muscle 
weakness predominantly or occasionally. They have specific features or may be 
less well defined (table 2 and table 3). 
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Table 2. Single families with distal myopathy and other distal myopathies. 
(Modified from Udd and Griggs 2001.) 
Table 3. Other myopathies that may present distal weakness   
(Udd and Griggs 2001). 
 
 
 
 
 
 
 
 
 
 
 
SINGLE FAMILIES WITH DISTAL MYOPATHY  GENE OR 
LOCI 
Variable onset distal  myopathy (Sumner et al. 1971) 
 
 
Distal  myopathy with vocal cord and pharyngeal weakness, MPD2  
(Feit et al. 1998) 
5q31 
 
Very late onset distal myopathy (Penisson-Besnier et al. 1998)  
Distal  myopathy with pes cavus and areflexia (Servidei et al. 1999) 
 
19p13 
Adult onset distal  myopathy (Felice et al. 1999)  
Juvenile onset distal  myopathy (Zimprich et al. 2000)  
Distal  myopathy with early respiratory failure (Chinnery et al. 2001)  
 
New Finnish distal myopathy, MPD3 (IV, V)  
OTHER DISTAL MYOPATHIES GENE OR 
LOCI 
Myofibrillar myopathies (desmin related) (Sjöberg et al. 1999, Vicart  et al. 
1998) 
 
DES, 
CRYAB 
Distal myopathy with sarcoplasmic bodies (Edström et al. 1980) 
 
 
Oculopharyngodistal myopathy (Satoyoshi and Kinoshita 1977)  
 
 
Facioscapulohumeral dystrophy, FSHD 
 
Central core disease 
Inclusion body myositis (IBM) Nemaline  myopathy 
Dystrophia myotonica DM1 Limb-girdle muscular dystrophy 2G 
Scapuloperoneal myopathy Limb-girdle muscular dystrophy 1C 
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Tibial muscular dystrophy (TMD) 
 
TMD was originally described in two different patient groups in Finland and it 
was not well understood whether the two groups represented the same disease 
(Laulumaa et al. 1989, Partanen et al. 1990, Udd et al. 1990). Classification of 
this new disorder was complicated due to distal and proximal phenotypes 
observed in the original large consanguineous kindred originating from the 
Larsmo Islands on the West coast of Finland (Udd et al. 1991a, Udd et al. 1992). 
Further, rimmed vacuoles were observed  only in muscle biopsies of patients 
originating from the Savo-Karelia region (Partanen et al 1994, Udd et al. 1992). 
A nation-wide survey revealed 66 patients with uniform clinical presentation 
and the term tibial muscular dystrophy was proposed (Udd et al. 1993). To date 
there are more than 200 patients examined and they have more than 150 known 
symptomatic relatives leading to a point prevalence of 7/100 000 TMD patients 
in Finland (Hackman et al. 2002).  
  
Clinical picture 
The first symptoms, weakness of ankle dorsiflexion and an inability to walk on 
the heels, occur after 35 years of age. On inspection, the tibial anterior (TA) 
muscles are found to be atrophic (fig. 1). The short toe extensor muscles remain 
intact. There is no sensory loss and the tendon reflexes remain preserved. The 
disease is very slowly progressive and weakness usually stays confined to the 
anterior compartment muscles of the lower legs. After 10-20 years, the long toe 
extensors become clinically involved leading to foot drop and clumsy walking. 
In some rare cases patients have developed weakness in their proximal leg 
muscles early in the course of the disease. At the age of 75 years one third of the 
patients show mild to moderate walking impairment due to proximal leg muscle 
weakness. Neither the upper limb muscles or facial muscles are not involved and 
cardiomyopathy has not been diagnosed in TMD patients. The overall clinical 
symptoms are mild: patients remain ambulatory throughout their lifetime and in 
the mildest form may not be aware of their condition at all. (Udd et al. 1992, 
Udd et al. 1993, Partanen et al. 1994).        
 
Serum creatine kinase (CK) levels are normal or slightly elevated. Normal nerve 
conduction velocities are observed in neurophysiological studies whereas EMG 
shows myopathic changes especially in the TA muscles: a reduced number of 
very low and short polyphasic motor unit potentials and frequent fibrillation 
activity (Udd et al. 1993, Partanen et al. 1994, Udd et al. 1998). Computed 
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Figure 1.  Lower legs of a 58-year-old 
male TMD patient. Ventral edges of 
the tibial bone are prominent due to 
the atrophy of the TA muscles. 
Symptoms of reduced ankle 
dorsiflexion had existed for 15 years. 
Figure 2. CT scan of the leg muscles of a 64-
year-old female patient with 8-10 years of 
symptoms and inability to walk on her heels. 
Selective fatty degeneration of the TA 
muscles is shown on both sides with an early 
degeneration of the right extensor hallucis 
longus muscle (arrowhead). 
tomography or MRI show selective involvement of TA muscles that are 
replaced by adipose tissue. In the late stages, the long toe extensors are also 
involved and there are patchy lesions seen in clinically unaffected muscles (fig. 
2) (Udd et al. 1991b, Partanen et al. 1994). 
 
 
 
  
 
 
 
 
Morphological findings 
Muscle biopsy findings vary with the site of biopsy and the duration of the 
disease. Affected anterior compartment muscles in early stages of the disease 
show myopathic changes: increased fibre size variation, increased number of 
internal nuclei, fibre splitting and occasional fibre necrosis, angular and 
basophilic fibres. The sarcomere structure appears to be intact when examined 
by electron microscopy (EM). At later stages, severe dystrophic changes are 
observed with loss of myofibres and replacement by fibrous connective tissue 
and fatty infiltration. Lipofuscin granules are observed near the nuclei. Rimmed 
vacuoles, non-storage autophagic vacuoles with typical granular staining in their 
periphery, are seen in the majority of the patients in the early stages, although 
their presence is not mandatory for the diagnosis. Rimmed vacuoles in TMD do 
not show immunoreactivity for tau, β-amyloid or β-amyloid precursor protein. 
On EM, the rimmed vacuoles are found to contain degenerative cellular debris 
material with degenerating mitochondria, dark granular material, membrane 
whorls, myeloid bodies, multiple small vesicles, tubular structures and 
occasional bundles of 15-20 nm filaments, which are not separated from the 
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Figure 3.  Muscle biopsy from the TA 
muscle of a patient with 1-2 years of 
clinical symptoms showing early changes: 
increased variation of fibre size, increased 
number of internal nuclei, angular 
atrophic fibres, hypertrophic fibres, one 
atrophic fibre with rimmed vacuolar 
change (arrow) and one split fibre. (H&E 
400x). 
Figure 4. Electron micrograph of a TA 
muscle biopsy showing the edge of a 
rimmed vacuole containing cellular 
debris, i.e. myeloid figures (arrow), 
small vesicular structures, amorphous 
material and a 15-20 nm filamentous 
inclusion (F). Bar 1 µm. 
sarcoplasm by a membrane (fig. 4) Clinically non-affected muscles show normal 
morphology or minor myopathic changes. (Udd et al. 1992, Udd et al. 1993, 
Partanen et al. 1994, Udd et al. 1998).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
            
 
 
 
 
Genetic studies 
The pedigree findings in TMD are consistent with autosomal dominant 
inheritance as there are affected family members in all generations in about 0.5 
proportion and there are male-to-male transmissions excluding X-chromosomal 
inheritance (Partanen et al.1990, Udd 1992a). There is no significant difference 
in disease severity between genders. In the highly consanguineous Larsmo 
kindred eight patients were described to suffer from severe proximal LGMD-
type of muscle weakness and atrophy, but the age of onset, the progression rate 
and severity varied. Three patients had good distal strength and remained 
ambulatory at an advanced age, whereas the others had also severe distal 
weakness and were wheelchair bound in early adulthood (Udd et al. 1991a). 
Limb-girdle type muscular dystrophy was found in a proportion of 0.246 in this 
pedigree and was suggested to result from a homozygous manifestation of the 
dominant gene (Udd 1992a). A genome-wide locus search was initiated in this 
pedigree with multiple inheritance models but it resulted in no significant 
linkage findings (Nokelainen et al. 1996). 
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TMD is a member of the Finnish disease heritage group currently consisting of 
36 diseases enriched in Finland due to population history (Norio 2003a,b,c). 
Because of the relative homogeneity of the Finnish gene pool, these diseases are 
mostly caused by one major mutation. The geographical background of the 
families with TMD patients show clustering in two areas, the Savo-Karelia 
region in eastern Finland and the west coast region of middle Finland. 
Genealogical studies back to the 16th century have not revealed connections 
between the groups (Udd et al. 1993). Since the islands of Larsmo and the 
lowlands on the neighbouring mainland were available for permanent living 
after the 13th century, the TMD mutation may have originated in Savo-Karelia 
and spread with the settlement to the Western coast.  
 
TMD outside Finland 
There has been considerable emigration from Finland during the last centuries. 
Genealogical studies have showed that members of the Larsmo kindred have 
moved to North America, Sweden, other parts of Europe, South America and 
Australia. They may have passed TMD to their descendants (Udd 1992b). TMD 
patients with Finnish ancestry have been diagnosed with verified mutations in 
Sweden, Germany and Canada. Two European families, from Lille in France 
and Brussels in Belgium, without connection to Finland, have been described 
with clinical, ENMG, CT, morphological and genetic findings that are 
compatible with TMD (de Seze et al. 1998, van den Bergh et al. 2003, III). 
 
Late-onset distal myopathy (LODM, Markesbery-Griggs) 
 
One family of French-English ancestry with seven distal myopathy patients has 
been described in the the United States. Their pedigree indicated an autosomal 
dominant inheritance pattern. The onset of the disease was between 46 and 51 
years of age when weakness of anterior compartment distal leg muscles, i.e. 
weakness of ankle dorsiflexion, developed. The disease showed slow 
progression to the upper limb finger and wrist extensor muscles and to the 
intrinsic muscles. Eventually the proximal leg muscles became involved and one 
of the patients lost the ability to walk in his 70s. Cardiomyopathy was diagnosed 
in two autopsy studies. Serum CK was slightly elevated. Nerve conduction 
velocities were normal. Frequent fibrillations and low amplitude short motor 
unit potentials were observed in the EMG of the affected muscles. (Markesbery 
et al. 1974) 
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Replacement of myofibres with adipose and fibrous tissue was common in 
biopsies of the atrophic muscles. Myopathic changes were encountered in less 
severely affected muscles e.g. a variation in fibre size, central nuclei, necrosis 
and several fibres with multiple vacuoles. Large basophilic sarcoplasmic masses 
and large non-rimmed vacuolated fibres are the major difference compared to 
TMD muscle biopsy findings. Focal homogeneous granular material observed in 
a minority of the fibres and streaming of Z-line and rod like clumps of Z-line 
material were EM findings at variance with TMD. Membrane bound autophagic 
vacuoles containing granular cytoplasmic degradation products and myeloid 
bodies were other EM findings. (Markesbery et al. 1974, Markesbery et al. 
1977). 
Limb-girdle muscular dystrophies (LGMD) 
 
Classification 
 
Limb-girdle muscular dystrophies are inheritable autosomal recessive or 
autosomal dominant muscular disorders where the hallmark of the disease is 
progressive muscular wasting and predominant involvement of the pelvic and 
shoulder girdle musculature (Bushby 1997). The LGMD group is greatly 
heterogeneous both in the clinical and genetic sense. Classification is based on 
the mode of inheritance (LGMD1 for the dominant forms and LGMD2 for the 
recessive forms) and further on the known genes and loci (table 4) (Bushby and 
Beckmann 2003).    
 
Clinical picture and laboratory findings 
 
The first symptoms in LGMD are weakness in either the pelvic or the shoulder 
girdle muscles or both simultaneously. At the disease onset, the distal, facial or 
extra-ocular muscles are usually spared but they may become involved later. 
The age of the onset varies from childhood to adulthood and the rate of 
progression varies from rapid to very slow. Some forms resemble severe 
Duchenne muscular dystrophy leading to loss of ambulation in 10-20 years 
when others have a milder course. Different mutation types partially explain the 
severity, but intrafamilial variation is also seen with the same mutation. Serum 
CK is always elevated in the recessive forms, at least when the disease process 
is active, and may be up to 200 times the upper normal limit. Asymptomatic 
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Table 4. Current classification of LGMD. 
http://www.neuro.wustl.edu/neuromuscular/musdist/lg.html 
 
 
 
NAME GENE PRODUCT LOCUS REFERENCES 
LGMD 1A myotilin   (MYOT) 5q22-q34 Speer et al. 1992, Hauser et al. 2000
LGMD 1B lamin A/C   (LMNA) (also 
mutated in AD Emery-
Dreifuss MD and partial 
lipodystrophy)  
 
1q11-q21 van der Kooi et al. 1997, Muchir et 
al. 2000 
LGMD 1C caveolin-3    (CAV3) (also 
mutated in rippling muscle 
disease) 
 
3p25 Minetti et al. 1998, McNally et al. 
1998 
LGMD 1D 
 
(= dilated cardiomyopathy 
CMD1F) 
6q23 Messina et al. 1997 
LGMD 1E 
 
- 7q Speer et al. 1999 
LGMD 1F - 7q32 Palenzuela et al. 2003 
LGMD 2A calpain  3   (CAPN3) 15q15-q21 Beckmann et al. 1991, Richard et 
al. 1995 
LGMD 2B dysferlin   (DYSF) (allelic to 
Miyoshi myopathy) 
 
2p13 Bashir et al. 1994, Bashir et al. 
1998, Liu et al. 1998 
LGMD 2C γ-sarcoglycan   (SGCG) 13q12 Ben Othmane et al. 1992, Noguchi 
et al. 1995, McNally et al. 1996 
LGMD 2D α-sarcoglycan   (SGCA) 
 
17q12-q21 Roberds et al. 1994, Piccolo et al. 
1995 
LGMD 2E β-sarcoglycan   (SGCB) 
 
4q12 Lim et al. 1995, Bonnemann et al. 
1995 
LGMD 2F δ-sarcoglycan   (SGCD) 5q33-q34 Passos-Bueno et al. 1996, Nigro et 
al. 1996 
LGMD 2G telethonin         (TCAP) 17q11-q12 Moreira et al. 1997, Moreira et al. 
2000 
LGMD 2H TRIM32   (putative E3  
ubiquitin ligase) 
 
9q31-q34 Weiler et al.1998, Frosk et al. 2002 
LGMD 2I fukutin related protein 
 (FKRP) (also mutated in 
MDC1C) 
 
19q13 Driss et al. 2000, Brockington et al. 
2001b 
LGMD 2J titin  (TTN) 2q31 III 
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carriers may show slight CK elevation. In the dominant forms, CK varies from 
normal up to 6 times the normal upper limit. EMG examinations show 
myopathic or dystrophic changes. Muscle imaging with CT/T1-weighted MRI 
reveals hypodensity/ increased signal intensity in the affected muscles and helps 
to specify the pattern of muscle involvement. Muscle biopsy findings are 
consistent with dystrophy or myopathy. Signs of neurogenic process, 
inflammation, metabolic or mitochondrial abnormalities are excluded. 
Guidelines for specific molecular diagnosis of LGMD relying on genetic and 
protein expression findings have been proposed. (Bushby 1997, Mahjneh 1999, 
Bushby and Beckmann 2003). 
 
Proximal and distal phenotypes in the same family 
 
As was mentioned earlier, both TMD and proximal LGMD phenotypes have 
been found in one Finnish kindred. After the clinical genetic study, the proximal 
phenotype was suggested to result from a homozygous state of a dominant gene. 
This phenomenon is not restricted to TMD. In the other late onset dominant 
distal myopathy, Welander myopathy (WDM), a possible homozygous state has 
been described twice. On the first occasion, seven out 16 children of affected 
parents had distal myopathy, and two of them had severe myopathy with early 
proximal involvement (Welander 1957). After the linkage finding in WDM 
another family with a similar presentation was described. One patient 
homozygous for the WDM founder haplotype had earlier onset of the disease, 
faster progression and later marked proximal leg muscle weakness. The parents 
had classical WDM and were heterozygous for the haplotype (Åhlberg et al. 
1999). 
 
A slightly different situation has been documented with the case of Miyoshi 
myopathy (MM) and LGMD2B, both recessively inherited disorders. After the 
overlapping linkage finding, MM and LGMD2B could be speculated to be 
allelic (Bashir et al. 1994, Bejaoui et al. 1995). This issue was addressed when a 
large consanguineous aboriginal Canadian kindred with nine muscular 
dystrophy patients was described. Seven patients had proximal myopathy of the 
LGMD type and two patients had distal phenotype consistent with MM. All the 
affected were shown to carry the same homozygous missense mutation in 
dysferlin with a similar reduction in dysferlin expression in both phenotypes 
(Weiler et al. 1999). In a large inbred Russian family with LGMD2B and MM 
phenotypes, patients were likewise homozygous for a missense mutation 
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(Illarioshkin et al. 2000) and in an Italian family, the patients were compound 
heterozygotes for dysferlin missense mutations (Liu et al. 1998). It was 
concluded that additional genetic and environmental modifying factors are 
involved in influencing the phenotype (Weiler et al. 1999). Moreover, patients 
with dysferlin mutations may also present with reduced ankle dorsiflexion and 
foot drop instead of the more frequent MM phenotype. However, even in these 
cases the posterior compartment muscles of the lower legs are severely affected 
(Liu et al. 1998, Illa et al. 2001). 
 
Molecular background of muscular dystrophies and myopathies 
 
Skeletal muscles are specialized to generate the force that enables movement. 
They are composed of long and multinucleated cells called muscle fibres. 
Muscle fibre has electrically excitable plasma membrane (sarcolemma) 
surrounded by extracellular matrix. In the cytosol reside sarcomeres, the 
contractile subunits. End-to-end linked sarcomeres make up myofibrils. Parallel 
myofibrils of muscle fibre are visibly striated in light microscopy. The pattern 
arises from the repeated and highly organized arrays of thin (I-band) and thick 
filaments (A-band). Polar thin filaments are composed of actin and actin 
associated proteins. Tropomyosin and the troponin complex bind actin alongside 
whereas tropomodulin and capZ cap the filament ends. Bipolar thick filaments 
consist of hundreds of myosin molecules assembled into a filament backbone 
with globular heads in an array on the filament surface. Myosin binding proteins 
C and H (MyBP-C and MyBP-H) are distributed alongside myosin filaments. 
There are also filament systems of titin and nebulin. Single titin molecules span 
one-half of the sarcomere and nebulin accompany actin filaments lengthwise. 
Individual titin molecules overlap each other both in the Z-disc and in the M-
line, thus forming a filament contig from one sarcomere to the next. In the 
middle of the sarcomere at the M-line, the myosin filaments are cross-linked 
with myomesin, M-protein and titin in a complex structure. The Z-disc anchors 
thin filaments from opposing sarcomeres making lateral boundaries for the 
sarcomere. Further, it serves as the anchoring site for cytoskeletal filaments (e.g. 
desmin) connecting the sarcomere to the sarcolemmal costamere and may have a 
role in signal transduction pathways. Cross-connecting structures are composed 
of α-actinin dimers and about a dozen novel molecules. The thick and thin 
filaments interact by transient cross-bridges of globular head domains of myosin 
molecules. During muscle contraction, the myosin binding sites of actin 
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filaments are exposed and hydrolysis of ATP drives the head domain 
conformational change causing the thin and thick filaments to slide past each 
other in series. (Stryer 1995, Squire 1997, Stromer 1998, Clark et al. 2002). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sarcolemmopathies 
 
Sarcolemma, the plasma membrane of muscle fibre, bears specific features since 
force generated by sarcomeres has to be transmitted through it to the  
surrounding extracellular matrix without damaging the membrane structure. 
This is enabled by costameres that anchor sarcomeric Z-discs and M-lines to 
sarcolemma and further to extracellular matrix proteins like laminin and 
collagen. Three different multimolecular structures (dystrophin glycoprotein 
complex (DGC), integrins/ focal adhesion complex and the spectrin based 
cytoskeleton) make up the costameres (fig. 6) (Clark et al. 2002). 
 
The advent of molecular genetic studies in muscular disorders began with the 
cloning of dystrophin, the gene defective in X-linked Duchenne and Becker 
muscular dystrophies (DMD, BMD) (Koenig et al. 1987, Hoffman et al. 1987). 
Dystrophin functions as a link between cytoskeletal actin and sarcolemmal β-
dystroglycan and is essential in maintaining other components of the DGC at the  
Figure 5. Schematic picture of the sarcomere showing thin (actin) and thick (myosin) 
filaments in association with titin and some other sarcomeric proteins. 
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Figure 6. Sarcolemmal dystrophin glycoprotein complex and integrin complex. 
Dystrophin, sarcoglycan, caveolin-3 and dysferlin mutations are discussed in the text. 
Mutations in skeletal muscle specific α7 integrin cause congenital myopathy with 
delayed motor development (Hayashi et al. 1998). Expression of α7β1 integrin is 
upregulated in dystrophinopathy, possibly as a compensatory mechanism (Hodges et 
al. 1997). Laminin α-2-chain (laminin2, merosin) mutations cause congenital 
muscular dystrophy with a secondary reduction of α7 integrin (Helbling-Leclerc et al. 
1995, Allamand et al. 1997, Cohn et al. 1999). Widely expressed type VI collagen 
genes are mutated in the rare dominant Bethlem myopathy with joint contractures 
(Jobsis et al. 1996, Lamande et al. 1998, Pan et al. 1998). Moreover, collagen VI
mutations cause LGMD with phenotype overlapping Bethlem myopathy (Scacheri et 
al. 2002). DG =dystroglycan, ss =sarcospan, CAV3 = caveolin-3, Dysf = dysferlin, DB 
= dystrobrevin, Syn =syntrophin, nNOS = neural nitric oxide synthase, FLN2 =γ-
filamin. (Figure modified from Clark et al. 2002.)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
sarcolemma (Ervasti et al. 1990, Rosa et al. 1996, Rybakova et al. 2000). 
Further, many sarcolemmal and subsarcolemmal proteins that associate with 
dystrophin are implicated in signal transduction (fig. 6) (Rando 2001). A 
tremendous amount of research has concentrated on pathogenesis in 
dystrophinopathies. There is evidence for deranged calcium homeostasis, 
increased susceptibility to oxidative toxins and increased membrane 
permeability upon stress in muscle fibres. One model suggests that dystrophin 
deficiency causes increased transient local membrane disruptions and inflows of 
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calcium. Calcium activates intracellular proteases and leads to a vicious circle 
with altered calcium channel activity and further inflows of calcium. Disturbed 
calcium homeostasis causes apoptosis and/or necrosis of muscle fibre. (Blake et 
al. 2002, Alderton and Steinhardt 2000). 
 
Studies on dystrophin resulted in purification of the sarcoglycan complex 
(SGC). SGC in skeletal muscle is composed of membrane spanning α-, β-, γ- 
and δ- SG and sarcospan (Ozawa et al. 1998, Crosbie et al. 1997). Subsequently, 
α-, β-, γ- and δ-sarcoglycans were found to be mutated in LGMD2D, 2E, 2C and 
2F respectively (table 4). The SGC is assembled en bloc to the sarcolemma 
while mutation in any one of the sarcoglycans may prevent targeting of the 
complex to the plasma membrane (Holt and Campbell 1998). Thus, loss of one 
SG or dystrophin often results in the absence or reduction of the whole complex 
including sarcospan (Ohlendieck et al. 1993, Crosbie et al. 1999). One function 
of the sarcoglycan complex may be to strengthen the dystrophin-dystroglycan 
axis connecting cytoskeletal actin to the extracellular matrix (Ohlendieck 1996, 
Blake et al. 2002). Many studies support functions in signalling as well (Yoshida 
et al. 1998, Hack et al. 1999, Betto et al. 1999, Crosbie et al. 2002, Thompson et 
al. 2000). 
 
Molecular genetic studies have identified other sarcolemmal DGC associated 
proteins, caveolin-3 and dysferlin, also to be mutated in LGMD. Caveolins are 
structural proteins involved in the formation of caveolae (small membrane 
invaginations) which participate in signalling and cellular transformation 
(Lisanti et al. 1995, Parton 1996). Muscle specific caveolin-3 mutations cause 
clinically variable dominant muscular phenotypes including LGMD1C, 
hyperCKaemia, distal myopathy and rippling muscle disease (Minetti et al. 
1998, McNally et al. 1998, Carbone et al. 2000, Betz et al. 2001). Caveolin-3 
binds to the same β-dystroglycan domain as dystrophin and competitive binding 
may regulate this interaction (Sotgia et al. 2000). Further, caveolin-3 interacts 
with subsarcolemmal nNOS and the developing T-tubule system (Parton et al. 
1997), and seems to interact with dysferlin according to reported reciprocal 
secondary defects (Matsuda et al 2001). Caveolin-3 mutant myopathic mice 
show increased activity of nNOS as well as the changes in DGC distribution and 
T-tubule abnormalities that are also observed in LGMD1C patients (Sunada et 
al. 2001, Galbiati et al. 2001, Minetti et al. 2002). 
 
 27
Dysferlin mutations cause LGMD2B, Miyoshi myopathy (MM) and distal 
myopathy with anterior tibial onset (Bashir et al. 1998, Liu et al. 1998). Thus, 
modifying environmental and genetic factors are suggested to be involved in the 
pathogenesis because identical mutations cause these phenotypes (Weiler et al. 
1999). Dysferlin is expressed at early embryonic stages and although dysferlin is 
not vital for myofiber assembly, altered dysferlin levels at a critical stage are 
hypothesized to contribute to the phenotypic variability (Anderson et al. 1999). 
Dysferlinopathy patients lack dysferlin at the plasma membrane and have intact 
caveolin-3 whereas in caveolinopathy the expression of both may be disturbed 
(Matsuda et al. 2001). Some secondary reduction in calpain 3 expression has 
been noted in LGMD2B patients but a potential dysferlin-calpain interaction has 
not been verified (Anderson et al. 2000, Vainzof et al. 2001). Recently, dysferlin 
was demonstrated to have a role in membrane repair. Dysferlin deficiency 
prevents Ca2+-dependent resealing of the sarcolemma after injury potentially 
leading to muscle degeneration (Bansal et al. 2003, Lennon et al. 2003). 
 
Sarcomere protein defects 
 
The contractile subunits, sarcomeres, make up the bulk of the striated muscle 
fibre. As a natural consequence mutations in sarcomeric molecules cause 
variable muscular phenotypes and cardiomyopathy. Thin filament protein 
defects are associated with nemaline myopathies (NM), a subtype of congenital 
myopathies. NM present typically generalized muscle weakness of variable 
severity ranging from neonatal death to late onset slowly progressive disease. 
The characteristic findings on muscle biopsy are dark red or purple nemaline rod 
clusters under sarcolemma or around the nuclei with Gomori trichrome staining 
(Sanoudou and Beggs 2001). On electron microscopy, the nemaline rods appear 
to be extensions of Z-discs, and in fact consist of actin, α-actinin and other Z-
disc proteins (Sanoudou and Beggs 2001). Autosomal recessive NM is caused 
by mutations in nebulin, skeletal muscle α-actin, α-tropomyosin, troponin T and 
dominant forms by mutations in α-tropomyosin, β-tropomyosin and α-actin 
(Laing et al. 1995b, Pelin et al. 1999, Nowak et al. 1999, Tan et al. 1999, 
Johnston et al. 2000, Ilkovski et al. 2001, Donner et al. 2002).  
 
Autosomal dominant distal myopathy of Gowers-Laing type (MPD1) has been 
genetically linked to a large region on chromosome 14 (Laing et al. 1995a, Voit 
et al. 2001, Mastaglia et al. 2002). Muscle biopsy shows myopathic changes and 
in some cases autophagic vacuoles and intranuclear inclusions of 15-20-nm 
 28
filaments. Sequencing of the β-cardiac myosin MYH7 gene, has revealed a 
missense mutation A1663P encoding the tail region of the myosin molecule in 
an Australian family (Meredith 2001). Myosin is thought not to be able to form 
its α-helical coiled-coil structure due to introduction of a proline (Meredith 
2001). Further, binding sites for myomesin and titin are located in the disturbed 
tail region. A nearby L1617 deletion of MYH7 has been associated with the 
disease in a German family (Udd et al. 2002). In addition, mutations in the 
MYH7 gene are the most common cause for the inherited hypertrophic 
cardiomyopathy. Especially missense mutations in the myosin head-neck region 
are known to alter the motor function (Seidman and Seidman 2001). The MYH2 
gene encoding the fast myosin heavy chain is mutated in AD childhood onset 
hereditary inclusion body myopathy (HIBM3) with joint contractures and 
external ophthalmoplegia (Martinsson et al. 2000). The myosin motor domain is 
altered by an E706K missense mutation. Breakdown of the sarcomeric proteins 
was suggested to have a role in the pathogenesis of rimmed vacuoles (Tajsharghi 
et al. 2002) 
 
Dominantly inherited LGMD1A is caused by missense mutations in myotilin, a 
novel protein identified through interaction with α-actinin (Salmikangas et al. 
1999, Hauser et al. 2000, Hauser et al. 2002). Myotilin interacts also with γ-
filamin (FLN2) and has direct actin filament cross-linking and stabilizing 
properties (van der Ven et al. 2000, Salmikangas et al. 2003). These myotilin 
interactions and correct timing of expression seem to be essential for myofibril 
assembly. It has been suggested that myotilin stabilizes the Z-disc structure 
(Salmikangas et al. 2003). This is supported by the streaming of the Z-lines 
observed in patient muscle biopsies. The identified mutations locate outside the 
α-actinin and γ-filamin interaction sites. Further, the mutant molecules are 
expressed and myotilin is correctly localized to Z-discs while α-actinin binding 
remains normal. This indicates that yet unknown interactions are disrupted 
(Hauser et al. 2000, Hauser et al. 2002). 
 
Telethonin (T-CAP) mutations cause recessive LGMD2G (Moreira et al. 2000). 
In addition to proximal weakness, some LGMD2G patients have early weakness 
in distal muscles, a few patients have cardiomyopathy. Rimmed vacuoles are 
found in their muscle biopsies while the sarcomeric ultrastructure remains intact 
(Moreira et al. 1997). The known mutations result in a premature stop codon and 
patient muscle biopsies show a deficiency of telethonin protein (Moreira et al. 
2000). Telethonin specifically binds titin Ig-domains Z1 and Z2 in the Z-disc. A 
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ternary complex of titin, telethonin and sarcoplasmic reticulum membrane 
protein, small splice variant of ankyrin-1, is implicated in organizing 
sarcoplasmic reticulum around the Z-disc (Gregorio et al. 1998, Mues et al. 
1998, Zou et al. 2003, Kontrogianni-Konstantopoulos and Bloch 2003). When 
telethonin was identified, the protein was found to localize to the A-band with 
myosin (Valle et al.1997). This observation remains unclear. Telethonin 
interacts with many signalling associated molecules and the muscle LIM protein 
(MLP) telethonin complex is suggested to be a component of the stretch sensor 
machinery in cardiomyocytes (Faulkner et al. 2000, Frey and Olson 2002, 
Furukawa et al. 2001, Nicholas et al. 2002, Knöll et al. 2002). Defects in MLP 
lead to dilated cardiomyopathy. 
 
Calpain 3 and myonuclear apoptosis  
 
Structural proteins are reasonable targets for mutation in muscular dystrophy. In 
this context it was surprising that LGMD2A is caused by defective calpain 3 
(Richard et al. 1995). Calpains are calcium-dependent cytosolic nonlysosomal 
cysteine proteases. Calpain 3, encoded by CAPN3, is the muscle specific 
member of this group (Sorimachi et al. 1989). In addition to four homologous 
domains found in ubiquitous calpains, it has three unique domains named NS, 
IS1 and IS2 (Sorimachi et al. 1989). Calpain 3 is subject to alternative splicing 
and the full-length protein is the major isoform found in mature muscle (Herasse 
et al. 1999). The IS2 domain contains a nuclear translocation signal and a titin 
binding site (Sorimachi et al. 1989, Sorimachi et al. 1995). Binding to titin may 
regulate calpain 3 activity by preventing autolysis (Sorimachi et al. 1995). 
Calpain 3 has been suggested to have a role in myofibrillar integrity and in 
muscle maturation and it is not expressed in the mature heart muscle (Spencer et 
al. 2002). In in vitro function studies, calpain 3 proteins with the LGMD2A 
mutations lack proteolytic activity (Ono et al. 1998, Jia et al. 2001). 
 
Necrosis is thought to account for myofibre destruction in most of the muscular 
dystrophies. However, at least LGMD2A seems to be an exception. Patients and 
capn3-defective mouse exhibit TUNEL-positive apoptotic myonuclei in muscle 
fibres, and possibly in satellite cells, reducing the regenerative capacity of the 
muscles (Baghdiguian et al. 1999, Richard et al. 2000). Alterations in the 
IκBα/NF-κB signalling pathway have also been demonstrated. NF-κB is a 
transcription factor promoting expression of cell survival genes (Baghdiguian et 
al. 2001). IκBα masks the NF-κB nuclear localization signal and the inactive 
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IκBα/NF-κB complexes reside in the cytosol. Upon activation, IκBα is degraded 
allowing NF-κB to enter the nucleus. NF-κB induces, among others, expression 
of IκBα, which then transfers NF-κB back to the cytosol (Baldwin 1996). 
Calpain 3 is able to hydrolyse IκBα and possibly controls IκBα turnover in vivo. 
TUNEL-positive myonuclei in LGMD2A show IκBα labelling and aberrant NF-
κB subsarcolemmal localization surrounding myonuclei (Baghdiguian et al. 
1999). It has been postulated that accumulation of IκBα in calpain 3 deficiency 
prevents NF-κB dependent expression of survival genes and makes myofibres 
vulnerable to death signals (Baghdiguian et al. 2001). The protective role of NF-
κB is supported by the finding that the NF-κB pathway is activated in 
inflammatory myopathies and to some extent in DMD (Monici et al. 2003). 
Some components of the ubiquitin-proteasome system are down regulated in the 
gastrocnemius muscle from calpain 3 deficient mice (Combaret et al. 2003). 
Ubiquination targets proteins to proteasome degradation in cells (Joazeiro and 
Weissman 2000). These findings suggest defective ubiquitination of specific 
targets and accumulation of altered proteins and/or dysregulation of the 
NFkB/IkBa pathway. Interestingly TRIM32, a putative E3-ubiquitin-ligase gene 
of the tripartite-motif family, is mutated in LGMD2H (Frosk et al. 2002).  
 
Glycosylation defects 
 
Post-translational modification of cell surface proteins with oligosaccharides is 
essential for their function in cell adhesion and signal transduction. Disruption in 
these processes has recently been recognized to cause muscular pathology. A 
deficiency of fukutin in Fukuyama congenital muscular dystrophy (FCMD) 
leads to hypoglycosylation of α-dystroglycan (Michele et al. 2002). α- and β-
dystroglycan, encoded by a single gene, are expressed in various tissues but 
different glycosylation isoforms exist (fig. 6) (Ibraghimov-Beskrovnaya et al. 
1993). Hypoglycosylation abolishes α-dystroglycan ligand binding, including 
binding to laminin (Michele et al. 2002).  
Fukutin-related protein gene (FKRP) was identified by a homology search with 
the fukutin sequence, and it was found to be mutated in one form of congenital 
muscular dystrophy (MDC1C). Sequence analysis predicted a similarity to 
glycosyltransferases and both fukutin and FKRP have been localized to the 
Golgi apparatus (Esapa et al. 2002). MDC1C patient muscle biopsies show 
reduction in α-dystroglycan immunostaining similar to FCMD and secondary 
deficiency of laminin α-2 suggests pathogenetic similarity to FCMD. FKRP was 
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also found to be mutated in LGMD2I. Variable reduction of α –dystroglycan 
expression was observed in muscle biopsy of these patients accompanied by 
deficiency of laminin α-2 in some cases. (Brockington et al. 2001a, Brockington 
et al. 2001b)  
GNE (UDP-N-Acetylglucosamine 2-Epimerase/N-Acetylmannosamine kinase) 
is the rate-limiting enzyme in the sialic acid biosynthesis pathway, one of the 
sugar residues found in glycoproteins (Keppler et al. 1999). GNE is mutated in 
h-IBM and Nonaka distal myopathy (DMRV) in addition to sialuria (Eisenberg 
et al. 2001, Kayashima et al. 2002). H-IBM and DMRV phenotypes overlap and 
they probably represent the same entity. The variability in phenotypes may be 
due to mutations in different domains of GNE or other modifying factors. 
 
Titin (TTN) 
 
It was noted early on that the thin and thick filament characteristics cannot 
explain all the features observed in muscle fibres. Subsequently, titin was 
identified independently as the elastic protein of the sarcomere and as the high 
molecular weight protein found in striated muscles (Maruyama et al 1977, Wang 
et al. 1979, Maruyama et al. 1981). Physiological roles for titin were established 
as titin degradation was shown to result in decreased passive tension of muscle 
fibres and immunoelectron microscopy studies revealed titin as an extendable 
filamentous protein spanning one-half of the sarcomere from Z-disc to M-line 
(Horowits et al. 1986, Fürst et al. 1988). This molecular giant (3700 kD in the 
soleus skeletal muscle) has been identified as the third filament system in the 
sarcomere besides the thick and thin filaments. Titin amino-termini are 
embedded in the Z-disc where titin filaments from opposing sarcomeres overlap 
(Gregorio et al. 1998). Central I-band titin constitutes the elastic part of the 
molecule and is composed of tandem Ig-repeats. The C-terminal region 
contributes to M-line structures where titin filaments from both sides of the 
sarcomere again overlap (Fürst et al. 1999). Thus, titin molecules provide a 
filament system extending the length of the myofibrils (fig. 5). Recent studies 
suggest a stoichometry of six titin filaments per one half myosin filament 
(Liversage et al. 2001, Knupp et al. 2002). Titin is associated with multiple 
roles: a scaffold in sarcomere assembly and molecular ruler of the thick filament 
length, an elastic spring that keeps contractile elements in place and finally a 
signal transducer (Trinick 1994, Labeit and Kolmerer 1995, Squire 1997, 
Gregorio et al. 1999, Machado and Andrew 2000, Clark et al. 2002).  
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Figure 7. Modular structure of titin molecule (soleus skeletal muscle). 
Molecular structure of titin 
 
A 294-kb gene located on chromosome 2q encodes titin (Bang et al. 2001, Pelin 
et al. 1997). 363 exons encode 38 138 amino acid residues (4200 kD). The titin 
structure is modular. About 90 percent of the molecule mass is composed of 90-
95 residue immunoglobulin C2 (Ig)-like and 100-residue fibronectin type III 
(FN3)-like domains. Both Ig- and FN3-domains have a globular structure 
composed of seven or eight antiparallel β-sheets (Improta et al.1998, Mühle-
Goll et al. 1998). The remaining ten percent consists of intervening unique 
sequences, one being a kinase domain while the others have no considerable 
homology to known proteins (fig. 7) (Labeit and Kolmerer 1995, Bang et al. 
2001).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A large number of splice variants adjust titins for different physiological 
requirements in cardiac and skeletal muscle fibres (Labeit and Kolmerer 1995, 
Bang et al. 2001) (http://www.embl.heidelberg.de/ExternalInfo/Titin/). Four to 
seven Z-repeats are expressed in the Z-disc titin and the longer isoforms are 
found in cardiac muscle (Gautel et al. 1996, Sorimachi et al. 1997). Major 
 33
splicing differences in the I-band titin explain size differences observed between 
skeletal (3350-3700 kD) and cardiac muscle (2970-3300 kD) (Freiburg et al. 
2000). Skeletal muscles express larger isoforms of the tandem Ig-repeat 
segments and a PEVK-region with the N2A domain (fig. 7). Cardiac isoforms 
have shorter Ig-repeat segments with reduced number of the Ig-domains and 
shorter PEVK domains. Further, the N2A domain is replaced by the N2B or 
N2BA domain in cardiac muscle (Freiburg et al. 2000, Trombitas et al. 2001). 
The A-band region has a conserved structure in all muscle types whereas the M-
line region of titin is expressed in two splice isoforms either containing or 
lacking the Mex5 exon, designated as Mex5 + and Mex5 – isoforms (Kolmerer 
et al. 1996). A C-terminally truncated 700 kD isoform having an alternative C-
terminus, novex-3, is expressed in both skeletal and cardiac muscle but is less 
abundant than the other isoforms (Bang et al. 2001).  
 
Functions of titin and interactions with sarcomeric proteins 
 
Z-disc and sarcomere assembly 
Titin is expressed amongst the first sarcomeric proteins during 
myofibrillogenesis and is observed in dot-like aggregates with α-actinin that 
further organize to precursory Z-discs coordinating filament assembly (Lin et al. 
1994, van der Loop et al. 1996, Gautel et al. 1999, Sanger et al. 2002). The 
aminoterminal 80 kD of the titin molecule spans the Z-disc (Gregorio et al. 
1998, Young et al. 1998). The first two Ig-domains (Z1 and Z2) bind telethonin 
in a conformation-dependent manner suggesting regulation of this interaction by 
phosphorylation (Gregorio et al. 1998, Mues et al. 1998). One function of 
telethonin may be linking titin filaments in the Z-disc (Zou et al. 2003). In 
addition, telethonin is a potential molecule in the stretch sensor machinery with 
muscle LIM protein (Knöll et al. 2002) 
 
Variably expressed 45-residue Z-repeats provide multiple binding sites for α-
actinin C-termini (Gautel et al. 1996, Sorimachi et al. 1997). The adjacent 
sequence insertion (Zq) has a single binding site for the spectrin like repeats of 
the α-actinin molecule (Young et al. 1998). Titin-α-actinin interaction is 
regulated by phosphatidylinositol 4,5 bisphosphate (Young and Gautel 2000). 
Titin, together with nebulin, are suggested to regulate the diversity of Z-disc 
widths observed in different striated muscle types, although the correlation is not 
straightforward (Millevoi et al. 1998, Luther and Squire 2002).  
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I-band titin, elastic spring 
Titin exhibits important mechano-physiological functions. The elastic properties 
of titin determine the passive tension of both skeletal and cardiac muscle. Titin 
helps to set the resting (slack) length of the muscle and further restores 
sarcomere length, and positions thick filaments at the centre of the sarcomere 
after stretching or contraction. Maintenance of the symmetrical thick and thin 
filament overlap is necessary for the sequential contractions by the sarcomeres 
(Horowits 1999). The I-band region is composed of tandem Ig-domain repeats, 
insertion of a PEVK domain (rich in proline, glutamine, valine and lysine 
residues) and a N2A domain in skeletal or the N2B/N2BA domain in cardiac 
muscle (fig. 7) (Labeit and Kolmerer 1995, Freiburg et al. 2000). The elasticity 
of I-band titin is determined by varying properties of these modules. Upon 
stretching with a low force these Ig-domains elongate without producing 
significant tension. The PEVK region unfolds at higher forces with a linear 
increase in passive tension (Linke et al. 1999, Li et al. 2001, Granzier and Labeit 
2002). In cardiac muscle the N2B region is capable of extending after the PEVK 
domain at increasing levels of stretch (Linke et al. 1999, Trombitas et al. 1999). 
Different muscles have varying elastic properties that can be explained by 
alternative splicing events in the I-band titin (Freiburg et al. 2000, Cazorla et al. 
2000). Stiffer cardiac muscle has the shortest isoforms of the I-band titins.  
 
I-band titin, regulatory functions 
Titin has been found to posses many unique regulatory mechanisms affecting 
the elastic and contractile properties of the muscle, such as the interaction with 
actin and nebulin in the PEVK region and modification of the N2B domain in 
cardiac muscle (Linke et al. 2002, Kulke et al. 2001, Yamasaki et al. 2001, 
Yamasaki et al. 2002, Neagoe et al. 2002, Golenhofen et al. 2002). The N2A 
domain binds the skeletal muscle specific protease calpain 3. However, the 
functional role of the titin calpain 3 interaction in the I-band is unknown. 
Implications for pathology exist as shown by the deletion of the N2A domain in 
the spontaneous MDM mutant mouse (Sorimachi et al. 1995, Garvey et al. 
2002). The PEVK domain interaction with nebulin may have a role in 
myofibrillogenesis (Ma and Wang 2002). 
 
A-band titin, scaffold for thick filament assembly 
Titin is thought to serve as a ruler for myosin filament assembly (Trinick 1994). 
This is supported by the regular super repeat structure of FN3- and Ig- domains 
of the A-band titin matching the myosin helix repeats (fig. 7) (Labeit et al. 
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1992). Titin FN3-domains bind to light meromyosin, the C-terminal portion of 
the myosin molecules (Houmeida et al. 1995). The gap of myosin crossbridges 
close to the end of thick filaments correlates with the stretch of FN3-domains 
possibly being the termination mark for myosin filaments (Bennett and Gautel 
1996). In the absence of titin, thick filament assembly is impaired (van der Ven 
et al. 2000b). FN3-domains also bind myosin heads, which may influence acto-
myosin interactions (Mühle-Goll et al. 2001). Another important binding partner 
of A-band titin is myosin-binding protein C (MyBP-C). MyBP-C molecules are 
arranged regularly in nine of the 11 thick-filament stripes where the first Ig-
domain of each titin super repeat serves as the binding site (Freiburg and Gautel 
1996). Thus, MyBP-C is thought to be involved in thick filament assembly and 
may regulate contraction (Winegrad 2000).  
 
M-line titin 
The M-line serves as an anchoring site for thick filaments in the middle of the 
sarcomere where myosin filaments are cross-linked to a complex structure with 
M-bridges, M-filaments and secondary M-bridges. M-bridges correspond to the 
electron dense M-lines observed in electron microscopy. The M-line is made up 
of myosin, titin, different isoforms of myomesin, M-protein and molecules 
involved in signalling and metabolism. C-terminal titin filaments from both 
sides of the sarcomere overlap in the M-line but direct interaction between titin 
molecules from opposite sides has not been shown. (fig. 8) (Fürst et al. 1999).  
 
A very intriguing part of M-line titin is a serine/threonine- kinase domain 
homologous to the myosin light chain kinase (MLCK) (Labeit and Kolmerer 
1995, Gautel et al. 1995). The kinase domain is highly conserved between 
species and it is supposed to be fundamentally important for muscle function. 
Characterisation of the kinase activation showed that it phosphorylates 
telethonin during early myofibrillogenesis in vitro but true physiological 
substrates remain to be clarified. (Mayans et al. 1998). The functional 
importance of the kinase region is highlighted as conditional deletion of the 
exons Mex1 and Mex2 is lethal in early embryogenesis and when introduced 
later causes muscle weakness, sarcomeric disassembly and death in postnatal 
mice (Gotthard et al. 2003). 
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Figure 8. Schematic representation of the molecular structure of M-line titin and 
associated proteins (modified from Fürst et al. 1999). Is7 encoded by the Mex5 exon is 
subject to alternative splicing and may be left out. Myomesin, M-protein and 
obscurin have modular structures similar to titin. Myomesin binding to titin is 
regulated by phosphorylation. M-protein has not been demonstrated to bind titin so 
far and its expression is restricted to cardiac and fast-twitch muscles.  Binding sites of 
the signalling molecules calpain 3, MURF-1 and FHL2-DRAL are indicated. DRAL 
has been suggested to link metabolic enzymes like CK to M-line. The localization of 
obscurin is obscure. Binding sites of M-line titin antibodies are indicated with arrows. 
(Oberman et al. 1997, Fürst et al. 1999, Auerbach et al. 1999, Ehler et al. 1999, Lange 
et al. 2002). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The second last titin exon (Mex5) codes for a unique sequence insertion (is7) 
and is alternatively spliced (Kolmerer et al. 1996).  Heart muscle expresses 
Mex5+ isoforms only. Fast-twitch muscles express Mex5- as the major isoform 
while slow-twitch muscles express both isoforms (Kolmerer et al. 1996). This 
variability may correlate with the electron microscopic differences seen in M-
lines of different muscle types (Kolmerer et al. 1996). Other interesting features 
of M-line titin are the existence of a putative phosphorylation site in the unique 
sequence insertion is4, the interaction and binding of creatine kinase, the 
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regulatory FHL2-DRAL and myomesin in the centre of the M-line (Labeit and 
Kolmerer 1995, Oberman et al. 1997, Lange et al. 2002). 
 
As mentioned above, titin contains at least two binding sites for the muscle-
specific protease calpain 3, one in the N2A domain and the second in the M-line. 
Interaction with Z-disc titin has also been suggested. The M-line binding site has 
been mapped to the is7 encoded by Mex5. The two different titin-calpain 3 
interactions are not equal when it comes to binding affinities and the binding 
region of calpain 3 itself. Mature cardiac muscle does not express calpain 3 and 
both titin binding sites are subject to alternative splicing. Thus, binding to titin 
may regulate calpain 3 activity in a muscle specific manner. M-line titin may 
also provide a scaffold for other molecules interacting with calpain 3. 
(Sorimachi et al. 1995, Kinbara et al. 1997). 
 
Novel titin interacting molecules 
Obscurin is a recently identified 800 kD striated muscle protein which has a 
modular structure similar to titin. However, it is expressed in low levels in 
skeletal and cardiac muscle (Young et al. 2001, Russell et al. 2002). During 
myofibrillogenesis, obscurin interacts with titin Z-disc Z9-Z10 Ig-domains and 
transfers to the M-line region later in differentiation (Young et al. 2001). The 
small Novex-3 titin isoform was found to interact with obscurin - providing a 
second binding site to obscurin and implicating obscurin-titin complexes with 
elastic properties (Bang et al. 2001). Obscurin has two kinase domains 
homologous to myosin light chain kinases (MLCK), a calmodulin-binding IQ 
motif and a Rho guanine nucleotide exchange factor domain, indicating a role in 
calcium dependent and G-protein coupled signalling (Young et al. 2001, Russell 
et al. 2002). Obscurin interactions with ankyrin-1 isoforms and titin are 
suggested to organize sarcoplasmic reticulum components in the Z-disc and M-
line (Zhou et al. 1997, Bagnato et al. 2003 Kontrogianni-Konstantopoulos and 
Bloch 2003, Kontrogianni-Konstantopoulos et al. 2003) 
 
Yeast two-hybrid screening with titin baits resulted in the discovery of a muscle-
specific RING finger protein-1 (MURF-1) (Centner et al. 2001, Dai and Liew et 
al. 2001). Subsequent yeast two-hybrid screens with MURF-1 as a bait led to the 
discovery of  MURF-2 and MURF-3 (Centner et al. 2001).  MURFs belong to 
the RING-B-box-coiled-coil proteins implicated in signalling, ubiquitination and 
transcription. MURF-1 binds to titin A168-A169 domains adjacent to the kinase 
domain, which has led to a suggestion that it may regulate kinase activity 
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(Centner et al. 2001). Some expression of MURF-1 has been observed in Z-discs 
and nuclei (Centner et al. 2001, McElhinny et al. 2002). M-line and thick 
filament structure are maintained by MURF-1 interaction with titin (McElhinny 
et al. 2002). Interestingly, MURF-1 has ubiquitin ligase activity and is 
upregulated in skeletal muscle atrophy. In fact, MURF-1 knockout mice are 
resistant to muscle atrophy and MURF-1 may be a key molecule in regulating 
protein degradation (Bodine et al. 2001). During myofibrillogenesis, MURF-2 
associates in sequential order with microtubules, myosin and titin. In mature 
cardiac muscle, it locates to the M-line and nuclei (Pizon et al. 2002). MURF-3 
locates to Z-discs, interacts with MURF-1 and MURF-2 and is involved in 
microtubule maintenance (Spencer et al. 2000). 
 
DRAL/FHL-2 (cardiac muscle four and a half LIM-only protein) binds titin in 
the I-band N2B-domain and the is2 domain in the M-line and may couple the 
metabolic enzymes creatine kinase, adenylate kinase and phosphofructokinase to 
the sarcomeric structures (Lange et al. 2002). Homologous FHL-1 and FHL-3 
proteins are expressed specifically in skeletal muscle but their binding partners 
have not been defined (Morgan and Madgwick 1999). 
 
Identification of disease genes 
 
Several approaches to identify disease-causing genes exist, once a disorder with 
Mendelian inheritance (monogenic) is characterized. The four main paths are 
functional cloning, the candidate gene approach, positional cloning and the 
positional candidate approach (Collins 1995). Which path is used is dependent 
on the level of prior knowledge of the functional defect in the disease and the 
patient/family material available.  
- Functional cloning is based on existing information of the biochemical defect 
or protein product. The amino acid sequence is used to design oligonucleotides 
that are further used to identify cDNA e.g. by screening transcript libraries. This 
requires no information on the chromosomal map position of the gene and used 
to be the conventional method in disease gene identification (Gitschier et al. 
1984, Ikonen et al. 1991).  
- The candidate gene approach is also based on prior knowledge of the 
pathogenesis of the disease. On the grounds of a hypothesis, probable defective 
genes are directly screened for mutations or families are used for linkage 
analysis to candidate gene loci.  
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- Positional cloning of a disease gene is based solely on chromosomal location 
of the disease gene (Rommens et al. 1989, Hästbacka et al. 1994). Pure 
positional cloning used to be a laborious method: After locus finding and 
refinement, a genomic clone contig (physical map) was created and identified 
transcripts were searched for mutations. The advancements brought by the 
Human Genome Project (HGP) has facilitated this method by providing genetic 
and physical maps of the human genome and most recently the complete human 
genome sequence (International Human Genome Sequencing Consortium 2001, 
Venter et al. 2001). Identification of genes within the linked region can be 
performed in silico and the physical mapping step is no longer needed. 
- The positional candidate approach has gained dominance over the above 
methods due to the HGP (Collins et al. 1995). Once the locus assignment is 
established with sufficient family material, pathogenetically likely genes, 
predicted genes or expressed sequence tags (EST) from the linked region are 
sequenced (Aittomäki et al. 1995).  
 
The Human Genome Project 
 
The Human Genome Project (HGP) was launched in the late 1980s when the 
National Human Genome Research Institute (NHGRI) was founded by the US 
Department of Energy (DOE) and the National Institutes of Health (NIH) in the 
United States. The goals for the HGP were to create genetic and physical maps 
and to sequence the human genome and the genomes of key model organisms in 
parallel, to develop technology supporting these objectives and to study ethical, 
legal and social aspects of human genome research (Collins and Galas 1993, 
http://www.genome.gov/). Other countries launched their own genome projects 
simultaneously. The International Human Genome Organization (HUGO) was 
created to coordinate the national projects (McKusick 1989).  
 
It may be stated that the HGP has reached all its goals. During the 1990s dense 
genetic maps based on polymorphic DNA markers were released (Gyapay et al. 
1994, Dib et al. 1996, Broman et al. 1998) as well as sequence-tagged site (STS) 
-anchored and gene based physical YAC/RH maps available from the public 
databases (Cohen et al. 1993, Hudson et al. 1995, Stewart et al. 1997, Deloukas 
et al. 1998). In February 2001, the International Human Genome Sequencing 
Consortium published the draft sequence of the human genome representing 
about 94 percent of the 3200 Mb human genome. Their strategy “hierarchical 
shotgun sequencing” was based on sequencing physically mapped BAC clones 
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(International Human Genome Sequencing Consortium 2001). Assembled 
sequences were released daily and made available in public databases. 
Simultaneously, the commercial organization Celera published another version 
of the human genome sequence that has not been freely available (Venter et al. 
2001). Their strategy was “whole genome shotgun sequencing” although they 
could use freely accessible mapping and sequence data produced by the HGP. In 
April 2003, the International Human Genome Sequencing Consortium declared 
that the HGP was successfully completed and the human genome has been 99 
percent sequenced with outstanding accuracy (http://www.genome.gov/).  
 
New goals have been set for the scientific community. The raw sequence has to 
be interpreted, how the genome functions as a whole and virtually all the 
molecular pathways it encodes have to be determined. Further, information of 
the human genome and other organisms has to be applied in practice in a manner 
that will benefit the health and well-being of all individuals. (Collins et al. 
2003). 
 
Genetic mapping    
 
The initial step towards disease gene identification with no functional evidence 
is to define the genetic locus for the disease gene. A genome wide scan and 
family-based linkage analysis is the conventional and straightforward method. 
The requirement is a well-characterized phenotype, because misdiagnoses 
potentially jeopardize the locus assignment. DNA samples from both affected 
and nonaffected family members are screened for genetic markers segregating 
with the disease phenotype. Two loci are linked if they are inherited together 
more often than would be expected by chance. This is based on the biology of 
meiosis. Alleles in the same chromosome are more likely to be separated by a 
recombination event the further they are apart. The genetic distance unit is a 
centiMorgan (cM), which is defined as the probability of the recombination 
event in meiosis. A one percent probability corresponds to one cM. The human 
genetic map is on average 3690 cM but the recombination frequency varies with 
the chromosomal region and sex (Gyapay et al. 1994, International Human 
Genome Sequencing Consortium 2001). Genetic and physical distances are 
comparable to some extent and roughly long chromosome arms have a 
recombination rate of 1cM per one Mb and short arms 2 cM per 1 Mb 
(International Human Genome Sequencing Consortium 2001). 
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The aim of statistical linkage analysis is to approximate the recombination 
fraction (Θ) between the disease and the marker locus and further determine the 
significance level. In the conventional likelihood (L) based method the odds 
ratio for or against linkage is calculated and the result is often expressed as a 
LOD (logarithm of odds, Z) score, which is the log10 of the likelihood ratio (Ott 
1991, Terwilliger and Ott 1994): 
 
Z(Θ) =  log10  L(linkage)           =  log10  L(Θ < 0.5)    
                       L( no linkage)                   L(Θ = 0.5)      
 
For monogenic diseases a LOD score >3 (odds ratio 1000:1) is considered 
significant evidence for linkage, while a LOD score < -2 (odds ratio 1:100) 
excludes the linkage (Conneally et al. 1985). The most probable distance of the 
disease locus from a tested marker is the recombination fraction that gives the 
highest LOD score (Ott 1991). Specific computer software is utilized to perform 
linkage calculations. For example the LINKAGE package programs may be 
used to calculate LOD scores using information from one marker (pair-wise 
analysis) or several markers (multipoint analysis) (Lathrop and Lalouel 1984, 
Terwilliger and Ott 1994, Cottingham et al.1993). The VITESSE algorithm has 
been developed to enable faster multipoint analyses (O’Connell and Weeks 
1995). These are parametric analyses i.e. they require prior knowledge of the 
mode of inheritance, disease gene frequency and penetrance. There are also non-
parametric analysis methods like GENEHUNTER to circumvent these problems 
(Kruglyak et al. 1996). 
 
After locus assignment by linkage analysis, the linked region may still be too 
large and contain too many genes for gene identification attempts. The use of 
isolated populations, like the Finns, may be beneficial as many diseases in such 
a population are caused by one major founder mutation (Peltonen et al. 1999, 
Norio 2003c). Linkage disequilibrium (LD), the non-random association of 
marker alleles in the linked loci, may help to restrict the critical region (Jorde 
1995). Further, haplotyping markers close to the vicinity of the disease locus 
may reveal a shared haplotype among affected family members and, on the other 
hand, indicate ancestral recombination events restricting the critical 
chromosomal region. This method has been used successfully to identify disease 
genes of the Finnish disease heritage (Peltonen et al. 1999). 
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AIMS OF THE PRESENT STUDY 
 
Prior to this study, genes and mutations underlying several inherited muscle 
disorders had been identified. However, for the clinically identified distal 
myopathies, no genes had been identified and only linkage assignment had been 
established for Miyoshi myopathy. A genomewide search for the TMD locus 
had been initiated with the original complex Larsmo pedigree without success. 
Meanwhile, diligent clinicians in Finland had identified more TMD families on 
clinical grounds and the available material for a linkage approach had become 
considerably larger and clinically well characterized. 
 
The aim of this study was to clarify the molecular genetic background of TMD 
and the specific aims of this study were: 
 
- To establish the genetic locus for TMD, 
- To restrict the critical chromosomal region, 
- To elucidate the relation of TMD to other described distal myopathies, 
- To identify the causative gene by the positional candidate approach, and 
- To study functional consequences of the putative mutation(s). 
 
During the TMD study, a novel distal myopathy with a distinct phenotype was 
discovered in a Finnish family. This triggered further aims of this study: 
 
- To clinically characterize the new form of distal myopathy, and 
- To begin molecular genetic studies of this novel entity. 
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SUBJECTS AND METHODS 
 
TMD patients and families 
One part of the family material consists of the original pedigree in which TMD 
was described with some rare patients displaying an LGMD phenotype (Udd et 
al. 1991). DNA samples had been obtained from patients and healthy family 
members prior to this study (Nokelainen et al. 1996). Family B used in the 
linkage studies represents part of this large consanguineous pedigree (fig. 11). 
Further, Family A used in the linkage studies has been described in detail earlier 
(fig. 10) (Partanen et al. 1994). Dr. B. Udd or Dr. H. Somer has evaluated 
diagnoses for the additional families and patients according to the criteria 
described in Udd et al. (1993). Altogether samples have been acquired from ten 
families with at least five affected persons, altogether 97 patients with TMD 
diagnosis, 6 with LGMD diagnosis and 77 healthy family members. An 
additional 32 patients belong to small families with 2-3 patients. 40 patients 
studied were without known affected relatives. Venous blood samples were 
collected for DNA extraction and/or immortalized lymphocyte cell cultures. 
Muscle biopsies were surgically obtained. Some biopsies, taken earlier for 
diagnostic purposes, were available. Samples were collected from informed and 
consenting individuals. The Ethical Board of Vasa Central Hospital approved 
the study protocol. DNA from members of one French family with 5 TMD 
patients and 9 healthy family members were included in the study (fig. 12) (de 
Seze et al. 1998). 
 
LODM family 
The LODM family studied represents a younger generation of the U.S. family in 
which the disease was originally described (Markesbery et al. 1974). Dr. Griggs 
and Dr. Markesbery established the diagnoses. Altogether, DNA samples were 
collected and available from 7 affected and 8 unaffected individuals, while for 
10 persons a diagnosis could not be determined due to the late onset of the 
disease (fig. 13). Foreign samples were collected according to the local ethical 
guidelines from informed and consenting patients and family members. 
 
Control samples 
In the linkage studies healthy family members served as control samples. The 
random sample from the Finnish population consisting of 56 DNA samples 
obtained for paternity tests and 160 from the Finnish Red Cross were analysed 
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to verify the TTN mutation. Samples were randomly numbered and could not be 
traced to any single person. A total of 93 French population samples were 
available at Généthon. 
 
DNA extraction 
DNA was extracted from whole-blood samples as described by Vandenplas et 
al. (1984) with modifications for the use of Phase Lock gel.  
 
Genotyping 
Polymorphic microsatellite markers were amplified by PCR (Aaltonen et al. 
1993). Fluorescently labelled products were electrophoresed with an ABI 377 
Sequencer and analysed with Genotyper 2.0 software (Perkin-Elmer, Applied 
Biosystems).  Alternatively, 15 loci were genotyped using 32P -γATP-labelled 
primers in PCR. The radioactive PCR products were separated in 5% 
polyacrylamide gel electrophoresis and the gels were subsequently dried. 
Products were visualized by autoradiography on Kodak X-Omat film and alleles 
were scored manually.  
 
Linkage analyses 
Two-point LOD-score calculations were performed using the MLINK option of 
the LINKAGE package programs (Lathrop and Lalouel 1984, Cottingham et al. 
1993, Schäffer et al. 1994). The SLINK option was utilized to estimate the 
informativeness of the family material (Ott 1989, Weeks et al. 1990). The 
VITESSE algorithm was used for multipoint likelihood calculations (O’Connell 
and Weeks 1995), for which TMD family B had to be subdivided, owing to 
multiple founders in the family. Autosomal dominant inheritance with complete 
penetrance was assumed and the gene frequency was set to .0001, young 
subjects (<35 years of age) were scored unknown in the linkage analyses, owing 
to the late onset of the studied diseases. The patients with LGMD phenotype 
(Family B) were considered as affected. Male and female recombination 
fractions were assumed to be equal. 
 
Haplotype analyses 
Haplotypes for the TMD locus on chromosome 2q were assembled manually 
allowing a minimum number of recombination events in each family. For 
sporadic TMD patients haplotypes were constructed according to the putative 
founder haplotype with a minimum number of ancestral recombinations. 
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Genomic clones 
Whitehead Institute WC2.15 contig includes five CEPH (Centre d’Etude du 
Polymorphisme Humain) YAC clones containing TMD linked markers that 
were purchased to establish a rough physical map of the linked region. After 
colony purification and DNA extraction, marker content of these clones was 
verified by PCR. The PAC library provided by Dr. P. de Jong was screened by 
PCR using primers for linked markers and known STSs in the critical region. 
Positive clones were colony-purified and DNA was obtained from subsequent 
cultures. 
 
Southern blot hybridisation 
DNA from three TMD patients, a TMD haplotype homozygous LGMD patient, 
an LGMD patient without the TMD haplotype and two control samples were 
analysed to identify major genomic rearrangements in TTN. DNA was digested 
with restriction endonucleases EcoRI, HindIII and PvuII (Amersham), and 
Southern blot hybridisation membranes were hybridised separately with titin 
cDNA PCR product pools hh1-9, hh 14-20 and hh45-53 recognizing 5’ region, 
A/I junction and 3’ regions of titin respectively (Southern 1975, Feinberg and 
Vogelstein 1984, Labeit and Kolmerer 1995). 
 
Sequencing 
The entire TTN coding region kown at the time including 348 of 363 exons was 
sequenced in TMD patient and control DNA. Specific primer pairs were 
designed manually or by Primer3 software to amplify fragments of the TTN 
gene or cDNA (Rozen and Skaletsky 2000). Genomic DNA or reverse 
transcriptase (RT)-reaction products were PCR amplified and run in agarose gels 
to confirm fragment size and specificity. The PCR products were purified 
enzymatically or by Qiagen columns (Hanke et al. 1994, Werle et al. 1994) and 
were sequenced using an ABI PRISM BigDye Terminator Cycle Sequencing 
Ready Reaction Kit (Chadwick et al. 1996). Extension products were 
precipitated and electrophoresed with an ABI PRISM 377 DNA sequencer 
(Perkin-Elmer, Applied Biosystems). Sequence data were analysed with 
Sequencing Analysis 3.3 and Sequencher 3.0 or 3.1.1 software (Perkin-Elmer, 
Applied Biosystems). 
 
SSCP Analysis  
SSCP analysis was used to screen patients and control samples for the putative 
TMD-causing 11 bp deletion/insertion in exon Mex6 of TTN (Vidal-Puig and 
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Moller 1994). PCRs were performed using a primer pair designed for a 184 bp 
fragment (forward CAGCATTGAATGAAGGCAAAG, reverse 
TCCACCATCTTGTTTCTGTACG). The PCR products were electrophoresed 
at 3 W for 15 hours in 0.5 x MDE polyacrylamide gel and the gels were stained 
using the silver staining method, were fixed and dried (Vidal-Puig and Moller 
1994, Donner et al. 2002). The gels were scanned at 300 dpi with an Agfa 
Snapscan 1236s image scanner. Adobe Photoshop 5.5 was used for image 
enhancement and detection of the bands. 
 
RNA extraction and RT-PCR 
Total RNA was extracted with a Rneasy Mini Kit (Qiagen) or a Purescript RNA 
Isolation Kit (Gentra) from either immortalized lymphocyte cell cultures or 
muscle biopsy samples that were surgically obtained and immediately frozen in 
liquid nitrogen and stored in -80°C. Complementary DNA was synthesized from 
1 µg of total RNA using 15 U AMV reverse transcriptase (Amersham), 1 U 
RNAse inhibitor (Rnasin, Promega), 10 pmol of dT30 primer and the four 
deoxynucleoside triphosphates at 0.4 mM concentration in 20 µl of buffer 
supplied with the enzyme (II). Alternatively, cDNA was synthesized by use of 
200 ng total RNA as template with 200 U M-MLV reverse transcriptase 
(Promega), 20 U RNAse inhibitor (Rnasin, Promega), 0.8 µM specific primer, 
0.6 mM deoxyribonucleoside triphosphate and buffer in a total volume of 25 ul 
(III). 
 
Western blot analysis 
Muscle biopsies of seven TMD patients and an LGMD patient homozygous for 
the TMD haplotype were snap frozen in isopentane chilled in liquid nitrogen to 
about -150°C, after which they were weighed and homogenized with 19 
volumes of SDS-PAGE sample buffer containing 4 M urea and 4% SDS. 
Proteins were denatured by incubation at +100°C for 5 minutes. Next, 8% gels 
were prepared, and different dilutions of pooled control homogenate were 
applied into each gel for quantitation. Both gel electrophoresis and Western 
blotting were carried out using standard buffers and protocols, with Bio-Rad 
Protean II xi Cell and Bio-Rad Trans-Blot cell (Hercules) (Laemmli 1970, 
Towbin et al. 1979). After electrophoresis, the proteins were transferred onto 
nitrocellulose membrane sheets and labelled with polyclonal telethonin antibody 
or monoclonal calpain3-antibodies NCL-CALP-2C4 and NCL-CALP-12A2 
(Novocastra Laboratories) which recognize 94 kD full size calpain3 and 
additional 30-kD and 60-kD protein fragments (Valle et al. 1997, Anderson et 
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al. 1998). DAB-detection was used with horseradish peroxidase-conjugated 
secondary antibody (DAKO P-0260). Residual proteins on gels were stained 
with Coomassie Brilliant Blue (R-250) after Western blotting. Dried blots and 
gels were used for densitometric analysis with Bio-Rad Quantity One-software. 
 
Immunohistochemistry and immunofluorescence studies 
Muscle biopsies from three TMD patients and one LGMD patient homozygous 
for TMD mutation were analysed with control samples. Initially antibodies were 
used against a total of 12 different epitopes of titin (x99a-x100, x105-x106, 
x112-x113, x118-x119, BK283-284, BD6, DB12, 9D10, McSM1, Mc3B9, 
NCL-TITIN, T11), α-actinin (NCL-α-ACT) and telethonin (cpf3a-4c) on frozen 
6-µm longitudinal muscle sections, fixed with ice cold acetone for 6 minutes 
(Novocastra Laboratories, Sigma). Antigenic detection was performed according 
to the manufacturer’s instructions using biotinylated antimouse and antirabbit 
secondary antibodies followed by ABC-DAB-detection (Vectastain Elite 
Universal Kit, Vector Laboratories) or with fluorescein isothiocyanate (FITC) 
conjugated secondary antibodies for immunofluorescence detection (DAKO F 
0232 and DAKO F 0205) (II).  
 
In the second stage exon-specific titin antibodies were obtained by expressing 
the Ig/FN3 domains A169/A170 (corresponding to the Mex1 exon containing 
the MURF-1 binding site) and the Ig domains M8/M9 (corresponding to 
Mex3/Mex4) in Escherichia coli essentially as described elsewhere (Gregorio et 
al. 1998). Rabbit polyclonal antibodies were raised to the purified antigens, and 
obtained antisera were affinity purified (Biogenes). Both polyclonal antibodies 
were used at 1:200 dilutions and the monoclonal anti-myomesin B4 (Grove et al. 
1984) was used at a dilution of 1:10 on unfixed frozen 6-µm longitudinal muscle 
sections. A Ventana Nexes automated immunostainer (Ventana Medical 
Systems) was employed for immunohistochemistry by the avidin-biotin-
complex method followed by 3,3’-diaminobenzidine (DAB) detection. 
Immunofluorescent detection was manually performed using FITC-conjugated 
secondary antibody (DAKO 0205, DAKO A/S) (III).  
 
Apoptosis studies 
The TUNEL staining method (an in situ cell death detection kit) and 
anticaspase3 antibodies were applied to detect apoptotic myonuclei from the 
biopsies of three patients with TMD, one TMD haplotype homozygous LGMD 
patient and samples of MDM mouse. The muscle biopsies were counterstained 
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with antidystrophin and DAPI (4,6-diamidino-2-phenylindole), appropriate 
secondary fluorescent antibodies were used and the sections were viewed with 
indirect immunofluorescence confocal microscopy. The TUNEL staining 
method was used according to the manufacturer’s protocol (Boehringer). 
Positive controls were obtained by incubating sections with 0.5 mg/ml 
deoxyribonuclease (DNase1) at room temperature before TUNEL staining. 
Further antibodies against Iκ-Bα and p65NF-κB were used on a set of slides to 
study IκBα/NF-κB expression in muscle cells. Methods used to detect apoptosis, 
the study of the IκBα/NF-κB route and indirect immunofluorescence confocal 
microscopy were essentially performed as described elsewhere (Baghdiguian et 
al. 1999). 
 
MDM mouse studies 
Age- and sex-matched normal control (C57BL/6J, C57BL/10), MDX 
(C57BL/10-mdx; dystrophin deficient) and MDM mice (C57BL/6J-mdm) were 
studied. Breeder mice of the MDM strain were obtained in 1992 from the 
Jackson Laboratory. The mice were no older than 12 weeks. Animals were kept 
in the animal care unit of the University of Bielefeld and of the University of 
Essen according to animal care guidelines. The Animal Care Use and Review 
Committee of the University of Essen approved all animal studies. The MDM 
skeletal muscle was homogenized with 1% SDS. After centrifugation, 100 µg of 
supernatant was resolved by SDS-PAGE (Anderson et al. 1998) on 3% to 15% 
linear gradient gels and transferred to nitrocellulose membranes (Towbin et al. 
1979). Nitrocellulose transfers were blocked in Blotto and subsequently 
incubated overnight with primary anticalpain3 antibodies Calp3c/11B3 and 
Calp3d/12A2 (Anderson et al. 1998). Immunoblots were then washed with 
Blotto and incubated for 1 hour with peroxidase conjugated secondary antibody 
(Boehringer Mannheim) at a dilution of 1:1000. 
 
Clinical examination of a Finnish family with MPD3 phenotype 
Clinical history regarding motor development, age and symptoms at onset, 
evolution of the disease, and other medical complications was recorded for all 
patients and two unaffected family members. A detailed muscle examination 
according to the Medical Research Council scale was carried out in order to 
assess the relative involvement of specific muscle groups. 
 
 
 
 49
Laboratory investigations in MPD3 
Muscle CT scans were performed on seven patients and three unaffected family 
members. An MRI of the upper limbs was performed for two patients. Serum 
CK activity was measured for six patients and for two unaffected relatives. 
Electrocardiogram and echocardiogram were carried out on four patients. 
Respiratory function was evaluated for four patients by performing spirometry 
and arterial blood gas analysis. Electrophysiological studies including 
electroneurography and EMG were conducted on the upper and lower limbs in 
multiple proximal and distal muscles of six patients. 
 
Muscle biopsy of the quadriceps, gastrocnemius, or tibial anterior muscles was 
obtained from five patients and from one unaffected member of the family for 
diagnostic purposes and they were used for this study after informed consent. 
The biopsies were processed using routine pathologic, histochemical, 
immunohistochemical, and ultrastructure studies by standard techniques. The 
antibodies used for immunocytochemical analysis were phosphorylated 
neurofilament protein/tau (SMI-31), dystrophin (Dy4/6D3 and Dy8/6C5), α-
sarcoglycan (Ad1/20A6), γ-sarcoglycan (35DAG/21B5), β-dystroglycan 
(43DAG/8D5) and on the western blots α2-laminin (80 kD fragment), calpain 3 
(Calp3d/2C4 and Calp3c/12A2) and dysferlin (NCL-hamlet). 
 
Blood samples for DNA extraction were obtained from 8 patients and 5 first-
degree relatives after obtaining their informed consent and in agreement with the 
Helsinki Declaration. The Ethical Board of the Kainuun sairaanhoito- ja 
erityishuoltopiirin kuntayhtymä approved the study protocol. 
 
Genotyping and linkage studies in MPD3 
In the first stage, microsatellite markers were genotyped for TMD and Welander 
distal myopathy loci on chromosomes 2q31 and 2p13 (I, Åhlberg et al. 1999). 
Haplotypes were constructed for segregation analysis. Further haplotypes were 
compared to the founder haplotypes observed in these disorders. A genome wide 
scan with nine family members and 553 polymorphic microsatellite markers was 
performed in collaboration with the Finnish Genome Center (Broman et al. 
1998). Subsequently, additional samples were available for the linkage studies 
and chromosomal regions that generated a two point LOD score >1.0 were 
genotyped using an additional 95 markers. Marker PCR products were 
electrophoresed on an ABI 377 Sequencer and analysed with Genotyper 2.0 
software or with Applied Biosystems 3730 DNA Analyzer and GeneMapper™ 
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3.0 software (Applied Biosystems). Marker order and distances were obtained 
from the Map Viewer at NCBI and the Center for Medical Genetics (at 
Marshfield Clinic) internet pages (International Human Genome Sequencing 
Consortium 2001, Broman et al. 1998). Linkage calculations were performed 
with a dominant mode of inheritance, full penetrance and a disease allele 
frequency of 0.0001. Male and female recombination fractions were assumed to 
be equal. Two-point LOD scores were calculated using the MLINK option of 
the LINKAGE v5.1 program (Lathrop and Lalouel 1984, Cottingham et al. 
1993, Schäffer et al. 1994). The SLINK option was used for simulation analyses 
(Ott 1989, Weeks et al. 1990). Multipoint linkage analyses were performed 
using GeneHunter (version 2.1_r3 beta) (Kruglyak et al. 1996). Haplotypes were 
constructed manually minimising the number of recombination events.  
 
Sequencing 
Genes encoding myosin light chain 1 slow-twitch muscle A (MLC1SA) and the 
muscle specific isoform of the ankyrin 1 (ANK1) were sequenced using DNA 
from three patients and two healthy family members (Hailstones and Gunning 
1990, Gallagher and Forget 1997). Primers were designed to amplify exons 
(Rozen and Skaletsky 2000). PCR products were sequenced using an Applied 
Biosystems BigDye® Terminator v3.1 Cycle Sequencing Kit (Chadwick et al. 
1996). An Applied Biosystems 3730 DNA Analyzer with accompanying 
Sequencing Analysis Software was used for base calling. Sequence data were 
analysed with Sequencher 4.0.5. software. (MLC1SA mRNA accession no. 
NM_002475, and muscle specific ANK1 mRNA accession no. AF005213). 
 
Bioinformatics 
During the experimental work for this thesis, the Human Genome Project has 
provided excellent tools for genetic research with accelerated speed. 
GeneMap´99 containing RH-mapping information on STSs, polymorphic 
markers, ESTs, mRNAs and genes and was utilized to search for positional 
candidate genes for TMD (Deloukas et al. 1998).  Later the human genome 
sequence was virtually completed and deposited to databases though the 
annotation process is still ongoing (International Human Sequencing 
Consortium 2001). Information from both databases can be viewed with search 
tools maintained by the National Center for Biotechnology Information (NCBI). 
Sequence alignments were carried out using BLAST programs (Altschul et al. 
1997) and sequence variations were viewed in single nucleotide polymorphism 
databases.  
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Table 5. Pairwise LOD scores obtained with four TMD families.
RESULTS AND DISCUSSION 
 
Tibial muscular dystrophy (TMD) 
Assignment of the TMD locus to chromosome 2q31 (I, unpublished results) 
 
To find a genetic linkage in TMD a genome wide scan with 279 polymorphic 
microsatellite markers was performed with samples from 11 affected and 6 
healthy members of Finnish TMD family A (fig. 10). In the simulation analysis, 
it was predicted that this family would provide significant evidence for linkage, 
with an expected average LOD score of 4.34. The primary screen revealed only 
one interesting region on chromosome 2q, with a maximum two-point LOD 
score >3. Positive LOD scores were observed with markers spanning a 43-cM 
region. A denser set of markers was analysed with additional members from 
family A and three other Finnish TMD families with a total of 48 affected 
individuals. The maximum two-point LOD score of 6.31 was obtained with the 
marker D2S364 (Θ=0.0) with family A. Further, significant LOD scores were 
observed in family B with markers D2S364 and D2S385 (fig. 11). Two small 
families showed positive LOD scores for the analysed markers and when 
information from the four families was combined, the maximum two-point LOD 
score of 10.14 (Θ=0.05) was obtained with the marker D2S364 (table 5). 
Multipoint likelihood calculations against a fixed set of markers assigned the 
TMD locus to be within close proximity of marker D2S324, which gave a 
maximum multipoint LOD score of 10.05 on top of the marker (Θ=0.0) (fig. 9). 
 
Markers      Θ = 0.0 0.01 0.05 0.1 
D2S2188 - ∞ 3.09 4.21 4.36 
D2S138 7.02 6.85 6.20 5.38 
D2S148 - ∞ 3.31 3.61 3.40 
D2S2173 3.35 3.27 2.95 2.54 
D2S300 6.13 6.00 5.46 4.78 
D2S385 5.02 4.90 4.41 3.80 
D2S324 4.05 4.07 4.44 4.25 
D2S2310 2.61 2.73 2.77 2.53 
D2S364 - ∞ 9.35 10.14 9.65 
D2S389 -6.22 3.02 5.02 4.32 
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Figure 9. Multipoint linkage analysis of the TMD locus against a fixed set of markers. 
The genetic intermarker distances of the clustered markers is about 1 cM 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Haplotype analysis reveals a common core haplotype 
Haplotypes were constructed for the linked markers. All affected individuals 
shared identical alleles from D2S138 to D2S364 in families A and B and one of 
the small families (fig. 10 and 11). The other small family shared the same 
identity in the interval from D2S138 to D2S324. This suggested one restricted 
core haplotype in all the families analysed. Furthermore, one healthy individual 
in family B shared the chromosomal haplotype of TMD up to marker D2S148. 
This set the proximal boundary for the TMD region. At this stage the core 
haplotype and the recombinations restricted the critical area to an approximately 
1-2 cM region between markers D2S148 and D2S2310. Six patients in the 
original TMD kindred from the Larsmo islands had an LGMD phenotype. Three 
individuals, with childhood onset of the disease and loss of ambulation in the 
twenties, were found to be homozygous for the disease haplotype (fig. 11). The 
other three individuals also clinically had an LGMD phenotype but the onset of 
the disease had been in adolescence and they lost ambulation in the 6th decade. 
Surprisingly, they were determined not to share the TMD haplotype at all after 
analysis of additional markers. This indicates a second LGMD gene segregating 
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Figure 10. Pedigree of TMD family A. The white symbols denote unaffected persons 
and the black ones affected patients. Individuals marked with a star were used in the 
genome wide scan. Haplotypes shared by affected individuals are marked grey. 
Figure 11. Pedigree of family B. Phenotype of the person marked with dots could not 
be concluded at the time of the linkage study and was scored unknown in the linkage 
analyses. Dashed symbols represent patients with early onset LGMD phenotype. 
Haplotypes shared by affected individuals and similar to family A are marked grey. 
The LGMD patients are homozygous for the observed TMD haplotype. 
in this consanguineous family and may be the reason why the earlier attempt to 
identify the TMD locus with this family was complicated (Nokelainen et al. 
1996). Multiple inheritance models were considered at the time, but we know 
afterwards that none of them was correct. This was the reason why statistically 
significant linkage was not reached despite the large size of the family. 
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Table 6. Disease associated haplotypes of 150 TMD patients.  The core haplotype 
is marked grey. Markers D2S138 and D2S148 have low heterozygosity, 
Frequencies were for D2S138 allele 6 0.27 and D2S148 allele 9 0.48 in the random 
Finnish control samples.  
 
 
 
 
 
 
Haplotype analysis of 150 Finnish TMD patients 
Collection of the TMD families and patient samples has been an ongoing 
process during this study. To narrow the critical region for the successive 
disease gene identification, haplotypes were constructed for an additional 102 
Number of  
observed  
haplotypes 
  D
2S
21
88
 
 D
2S
13
8 
 D
2S
14
8 
 D
2S
21
73
 
 D
2S
30
0 
 D
2S
38
5 
 D
2S
32
4 
 D
2S
23
10
 
 D
2S
36
4 
78 7      6     9 4 4 8 2 8 10 
8 7 6 9 4 4 8 2 8 13 
5 9 6 9 4 4 8 2 8 10 
5 4 6 9 4 4 8 2 8 10 
4 7 6 9 4 4 8 2 8 8 
3 7 6 9 4 4 8 2 8 5 
3 7 6 9 4 4 8 2 9 13 
4 5 6 9 4 4 8 2 8 10 
2 6 6 9 4 4 8 2 8 10 
1 7 6 9 4 4 8 2 8 11 
1 7 6 9 4 4 8 2 9 6 
1 9 6 9 4 4 8 2 8 7 
1 6 6 9 4 4 8 2 8 9 
1 6 6 9 4 4 8 2 8 8 
1 4 6 9 4 4 8 2 9 4 
1 9 6 9 4 4 8 2 8 13 
1 6 9 9 4 4 8 2 8 10 
1 7 6 6 4 4 8 2 8 10 
1 7 6 8 4 4 8 2 8 10 
20 9 6 9 3 4 8 2 8 10 
3 7 6 9 3 4 8 2 8 10 
1 7 6 9 3 4 8 2 8 8 
1 9 6 9 3 4 8 2 8 5 
obligatory 
recombinations           
1 4 6 9 3 4 8 2 8 10 
1 7 6 9 4 4 8 2 9 3 
1 4 5 9 4 4 8 2 8   
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Figure 12. The French TMD family. Haplotyes shared by affected individuals are 
marked  grey. Two-point LOD scores for the markers at Θ = 0.0 are displayed next to 
the haplotypes. 
Finnish TMD patients adding up to 150 analysed cases. Haplotype analyses 
revealed the most common haplotype 9-4-4-8-2-8 for the TMD patients. A total 
of 116 out of 150 disease chromosomes showed this haplotype. Some allelic 
variation was seen with the centromeric markers D2S148 and D2S2173 and 
telomeric marker D2S2310. All 150 disease chromosomes carried a core 
haplotype of 4-8-2. The core haplotype and three obligatory recombinations 
restricted the disease haplotype between markers D2S2173 and D2S2310 
consistent with the linkage analyses (table 6). TMD families show an uneven 
geographical distribution in Finland with clusters of cases on the western 
coastline and in the eastern Savo-Karelia region. The same core haplotype was 
found from the disease alleles in both clusters as further evidence for one 
founder mutation. To some extent, these haplotypes have diagnostic value when 
symptomatic patients are studied.  
 
TMD in a French family 
After assignment of the TMD locus to chromosome 2q, one French family was 
analysed. Five patients in the family showed a TMD phenotype clinically 
identical to the Finnish patients. Linked markers were genotyped with samples 
from the five affected patients and five healthy relatives. The LOD scores did 
not reach significant level as expected by the simulation analysis; however, they 
were positive except for marker D2S300. Haplotypes were constructed and all 
the affected were found to share the same haplotype which was not present in 
their healthy relatives (fig. 12). This haplotype is dissimilar to the Finnish one. 
Thus, an independent TMD-causing mutation was thought to have arisen in this 
family at the same chromosome 2q locus. Moreover, one of the patients was 
recombinant for the centromeric markers and combined with the earlier data the 
critical TMD region spans between markers D2S300 and D2S2310. (de Seze et 
al. 1998). 
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Figure 13. LODM family pedigree and haplotypes. Two-point LOD scores 
for the markers at Θ = 0.0 are displayed next to the haplotypes. 
Linkage studies with a late-onset distal myopathy family (LODM) 
When TMD was described, it was noted that it resembles LODM clinically 
(Markesbery et al. 1974). Both diseases have late onset and their symptoms 
begin from the anterior tibial muscles. However, LODM progresses to proximal 
and hand muscles and eventually leads to loss of ambulation. The original 
pedigree, in which LODM was described, was studied for linkage with the TMD 
associated markers. Diagnosis could be confirmed for six patients and six 
healthy relatives. Pairwise LOD scores did not reach significant level: the 
highest LOD score of 2.24 was found with marker D2S2310 (Θ=0.0). 
Multipoint analysis however settled the locus to be in close proximity of 
markers D2S385 and D2S324 with a maximum multipoint LOD score of 3.38. 
All the affected individuals share the same haplotype providing further evidence 
for the linkage (fig. 13). TMD and LODM are linked to the same markers on 
chromosome 2q and could be considered as allelic disorders. Some families 
representing distal myopathy have been tested for the TMD linked markers 
without evidence for linkage (Felice et al. 1999, Chinnery et al. 2001). Linkage 
in one family could not be excluded or verified (Penisson-Besnier et al. 1998, 
unpublished data). The heterogeneity is not surprising and is not restricted to the 
distal myopathies, since e.g. an LGMD phenotype may be caused by mutations 
in at least fifteen different genes (table 4). On the other hand, late-onset 
autosomal dominant myopathy with proximal muscle weakness, early 
respiratory failure and characteristic cytoplasmic bodies found in muscle biopsy 
was linked to chromosome 2q24-q31 overlapping the TMD locus (Edström et al. 
1990, Nicolao et al. 1999). The phenotype associated with chromosome 2q31 
was expanded further to dilated cardiomyopathy (Siu et al. 1999). 
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Figure 14. Markers blotted 
against genomic sequence. The 
genetic distances between 
markers are as obtained from the 
Center for Medical Genetics 
(Marshfield) map. WI-9271 is a 
STS marker located in TTN 3’ 
end while markers D2S324 and 
D2S385 are both found in 5’ 
introns of the gene 30 kb apart. 
Search for TMD causing gene and mutations (II, III) 
 
TMD physical region – revised 
After the locus assignment had been confirmed, the physical mapping databases 
were explored for the marker order and genes in the candidate region. The 
Whitehead Institute STS based physical YAC map was available at the time. 
Clones 935-E-10, 930-H-10 and 788-A-10 containing the linked markers were 
obtained and the marker content was confirmed. The 3’ region of the TTN gene 
(STS marker WI-9271) was within the region of interest. Additional primers 
designed for other parts of the gene confirmed that the entire coding region was 
present in the YAC clone 930-H-10. RH-assay had demonstrated that the 
orientation of the TTN gene is 3’ to 5’ from the centromere (Pelin et al. 1997). 
At this point TTN became the major positional and functional candidate gene for 
obvious reasons: It is expressed in skeletal and heart muscle in different 
isoforms and has major structural and physiological functions in the sarcomere. 
No other muscle specific transcripts were within the region. Even now, when the 
genomic sequence is available, there are no such genes among the 30 annotated 
or predicted genes in the critical area. There is some inconsistency between the 
genomic sequence and genetic distances over the region. Different maps give 
values 0-1 cM between markers D2S324 and D2S2310, which is not present in 
the RH-mapping panels. However, the physical distance between them is about 
2.5 Mb in the finished sequence (fig. 14). Yet, fiber-FISH experiments with 
BAC clones No. 14104 and No. 23155 used for TTN genomic sequencing 
(kindly provided by Dr. Labeit) and PACs screened with the linked markers 
approximate the distance to be between 0.55 to 0.8 Mb (S. Kilpinen, 
unpublished data).  
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TTN mutation screening 
The size of the candidate gene TTN was discouraging. The TTN gene, although 
compact, encodes mRNAs up to 100 kb. Full-length cDNA had been published 
as well as the M-line genomic sequence. Additional genomic sequences were 
available to us prior to publication (kindly provided by Dr. Labeit). Exploration 
for possible disease causing alterations was made step by step. Southern blot 
hybridisations were performed with TTN cDNA PCR product pools to detect 
gross rearrangements. The fragment patterns produced by multiple restriction 
enzymes did not show any differences between patients and controls. Further, 
several titin antibodies showed normal labelling in muscle biopsies giving 
evidence against major rearrangements (II). TMD does not affect heart muscle. 
For this reason skeletal muscle expressed tandem Ig-repeat exons were 
sequenced. In addition, N2A and Mex5 calpain3 binding sites and the Z1-Z2 
telethonin binding site were sequenced. Several polymorphisms were detected 
but none segregated with the disease. Finally, the attempt to sequence the whole 
gene was undertaken in collaboration with Dr. Richards’s group at Généthon 
and 348 of the 363 exons were sequenced.  
 
TMD is caused by Mex6 mutations in TTN 
In the Finnish TMD samples, a unique alteration was identified in Mex6, the 
363rd and the last exon of TTN. Mex6 of TTN encodes an Ig-domain that is 
localized at the periphery of the M-line lattice next to calpain3 binding Mex5/ 
Is7 (Kinbara et al. 1997). The alteration consists of an 11-bp change, 
AAGTAACATGG→ TGAAAGAAAAA, at position 293,269-293,279 in the 
TTN sequence and changes four amino acids Glu-Val-Thr-Trp→Val-Lys-Glu-
Lys but does not cause a frame shift or a premature stop codon. Each of the four 
residues is changed to an amino acid of another charge, and the overall charge is 
changed from acidic to basic. This sequence variation had not been reported 
earlier. Further, the altered segment is relatively well conserved between 
humans, mice, chicken and pigs. The 11-bp change was easily detected by SSCP 
analysis. SSCP studies showed that this mutation did not occur in the 216 
Finnish unaffected population control individuals tested. The change showed 
cosegregation with TMD in 12 unrelated pedigrees, in agreement with full 
penetrance after the age of 35. One family was an exception: three offspring 
aged 50-55 years did show the mutation without clinically manifesting the 
disease. However, in this family, the transmitting affected parents in the older 
generation had very late onset of symptoms at 65 years. These three individuals 
are followed up for detection of exceptionally late manifestation. This 11-bp 
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Figure 15. SSCP analysis of TTN exon Mex6 including the TMDFin mutation strand.
Analysis is performed with TMD patients, LGMD patients homozygous for TMD 
haplotype and control samples. The migration of PCR products matches the 
haplotypes and phenotypes of the patients. Arrows mark the bands indicating the 
mutation. Samples are denoted 1-16, w/w = sequenced wild-type control, w/m = 
sequenced TMDFin heterozygote, m/m = sequenced TMDFin homozygote, L = 100-bp 
DNA ladder. 
change could safely be concluded to represent the TMDFin mutation. The 
TMDFin deletion/ insertion represents a very unusual type of mutation. Neither 
an inversion nor a secondary loop in the area has supporting evidence. The 
mutation may have originated from recombination.  
 
SSCP analysis for the Mex6 region on DNA samples of the French TMD family 
did not show any aberrant bands. However, sequencing samples from the 
affected persons in this family revealed another potential mutation in Mex6 at 
position 293,357. This changed codon CTG to CCG (Leu→Pro). Both residues 
are neutral hydrophobic. The variant cosegregated with the phenotype and was 
not present in 93 French unaffected population control samples analysed by 
sequencing. Further the mutation was not found in the major SNP databases and 
is denoted TMDFra in the following text. A third TMD associated mutation has 
been reported in the Mex6 exon at position 293,329 changing Ile→Asn in a 
Belgian 2q31 linked TMD family (TMDBel, van den Bergh et al. 2003). 
Sequencing of the Mex6 region with the LODM patient samples has not 
revealed any changes. 
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SSCP may be utilized in TMD diagnostics 
Figure 15 shows SSCP analysis of patients and controls. There is a marked 
difference observed between wild type and TMDFin mutated alleles because of 
the size of the altered area. The analysed Finnish patients show a uniform 
banding pattern as expected since a founder haplotype was observed in the 
earlier studies. The percentage of the major founder mutations in the different 
Finnish disease heritage diseases varies but is in most of the cases above 90 
percent (Peltonen et al. 1999). Thus, SSCP analysis of the TMDFin mutation may 
be used as a diagnostic test for TMD in Finland. Yet other TTN mutations, 
which remain undetected in the SSCP analysis, may cause the TMD phenotype. 
This has to be taken into account when analysing diagnostic samples or giving 
genetic counselling.  
 
Homozygous TMDFin mutation results in a novel form of recessive LGMD 
(LGMD2J) 
Three LGMD patients in the original TMD pedigree were homozygous for the 
TMDFin mutation as predicted by the haplotype analyses. The disease course of 
TMD is mild and may not be recognized by the affected person. There is a 
possibility that LGMD arises in the offspring of mildly affected or 
presymptomatic parents heterozygous for TTN mutations. Thus TTN is proved 
to be one of the genes causing LGMD and is denoted as LGMD2J (Bushby and 
Beckmann 2003). This type of inheritance model is rare among muscular 
dystrophies and myopathies. However, in Welander myopathy (WDM), there 
are possible homozygous patients with earlier onset of the disease, faster 
progression and eventually marked proximal leg muscle weakness (Welander 
1957, Åhlberg et al. 1999). One of these patients has been available for 
genotyping studies and has be confirmed to be homozygous for the WDM 
founder haplotype (Åhlberg et al. 1999). 
 
Consequences of the TMDFin mutation (II, III) 
 
Both mutant and wild type alleles are expressed 
RT-PCR and sequencing the Mex5/Mex6 was performed with cDNA from 
biopsy samples of the tibialis anterior muscle from a heterozygous TMDFin 
patient. The results showed that the Mex5/Mex6 cDNA sequence is indeed 
heterologous and that both wild type and mutant RNAs are expressed in the 
affected muscle. The sequences were in frame, indicating that the mutation does 
not affect the splicing of these exons. 
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Figure 16. Immunostaining of muscle sections with titin M8/M9 antibody (A-C) 
and A169/170 antibody (D-F) detected by FITC. Unaffected control (A) and 
TMDFin heterozygous patient (B) have normal labelling with M8/M9 antibody, 
which shows M-line striated labelling pattern. TMDFin homozygous LGMD patient
(C) is missing M8/M9 labelling altogether. A169/A170 labelling in control (D), 
TMDFin heterozygous patient (E) and TMDFin homozygous LGMD patient muscle 
sections (F) are identical. 
Loss of epitope recognition by M8/9 antibody in TMDFin homozygote 
Screening of titin with twelve antibodies had showed normal striated labelling of 
patient muscle in immunohistochemical analyses (II). Specific antibodies 
against M8/M9 epitopes encoded by Mex3/Mex4 exons and A169/A170 
epitopes preceding the titin kinase domain were tested in the second phase (III). 
Immunohistochemical analyses of muscle biopsy samples of a TMDFin 
homozygous LGMD patient indicated a loss of the M8/M9 titin epitopes when 
either DAB or FITC detection methods were used. Three TMDFin heterozygous 
patients and a control individual showed normal cross-striated sarcomeric M-
line-specific labelling (fig. 16).  
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Figure 17. Western blotting with two different calpain 3 antibodies in TMDFin
heterozygous TMD patients and TMDFin homozygous LGMD patient. Proteins on 
blots were labelled with either NCL-CALP-2C4 or NCL-CALP-12A2 antibodies, 
followed by DAB detection. Approximate molecular masses are shown on the left. 
C = pooled control homogenate, C100 = 100% control homogenate, C70 = 70%
control homogenate dilution etc. 
The nearby A169/A170 titin epitopes could be detected in biopsy samples from 
both TMDFin homozygous and heterozygous patients. Further, the M4 domain of 
titin binds myomesin, an important structural protein of the M-line. Labelling of 
myomesin was normal suggesting unaltered titin binding. In conclusion, 
immunohistochemical data suggest the specific loss of titin epitopes C-
terminally of M4 domain. This localized titin defect appears to have no effect on 
sarcomeric ultrastructure in TMD. 
 
The TMDFin mutation in TTN results in a secondary calpain 3 deficiency 
Titin binds muscle specific calpain 3 at two characterized sites. To find out 
whether mutation in TTN would have an effect on calpain3 in a patient’s 
muscle, Western blot analysis was performed with two calpain 3 antibodies. 
Calpain 3 was clearly deficient in TMDFin homozygous LGMD patient. Calpain 
3 could not be detected with the NCL-CALP-2C4 monoclonal antibody when 
some residual expression was observed with the NCL-CALP-12A2 antibody. 
Calpain 3 amounts varied in the muscle samples of the TMDFin heterozygous 
patients, some showed decreased calpain 3. Immunodetection with a telethonin 
antibody, another titin ligand, showed no abnormalities. 
 
 
 
 
 
 
 
 
 
 
 
 
 63
Apoptosis and a disturbed IκBα/NF-κB pathway similar to LGMD2A 
Calpain 3 deficiency, caused by primary calpain 3 mutations, has been 
associated with myonuclear apoptosis and perturbation of the IκBα/NF-κB 
signalling pathway (Baghdiguian et al. 1999). To find out whether secondary 
calpain 3 deficiency could cause similar alterations, the TUNEL staining method 
detecting DNA fragmentation and anticaspase3 immunolabelling were used on 
patient muscle biopsies. Apoptotic myonuclei were observed in the muscles of 
the TMDFin heterozygous patient and a greater frequency of them were seen in 
the TMDFin homozygous LGMD patient. Staining was detected in centralized 
myonuclei and in small clusters. All the TUNEL-positive myonuclei were 
anticaspase3 positive, but anticaspase3 staining positive fibres were more widely 
distributed. Normally both IκBα and NF-κB are evenly distributed in the 
cytoplasm, a situation which was seen in the control sections. In the samples 
from both the heterozygous and homozygous patients IκBα was found to be 
aberrantly relocated in the TUNEL-positive myonuclei. Further, expression of 
NF-κB was subsarcolemmal. These findings are similar to those observed in the 
primary calpainopathy in LGMD2A and may be involved in the pathogenesis of 
TMD/ LGMD2J.  
 
MDM mouse – a possible model for TMD/ LGMD2J (II) 
 
A spontaneous recessive mutation in the mouse causes severe progressive 
skeletal muscle wasting, muscular dystrophy with myositis (MDM) (Lane 
1985). MDM mice are reduced in weight and have shortened lifespans 
(Heimann et al. 1996). Muscles postnatally degenerate and regenerate and there 
is notable overproduction of satellite cells (Heimann et al. 1996). The MDM 
mutation has been linked to the proximal part of chromosome 2, syntenic to 
human chromosome 2q31 region with the genes for nebulin, titin and nicotinic 
acetylcholine receptor α1-subunit (Müller-Seitz et al. 1993). Based on this and 
the finding of a secondary calpain 3 deficiency in the TMDFin homozygous 
LGMD patient, we analysed MDM skeletal muscle for expression of calpain 3. 
MDM muscles showed a severe reduction of the 94 kD band of calpain 3 with 
antibodies calp3c/11B3 and Calp3d/12A2 (II). Further, TUNEL positive 
myonuclei were found in the muscle sections and alterations in IκBα and NF-κB 
labelling similar to patients were observed, although less pronounced. 
Subsequently a Ttn mutation causing MDM has been identified (Garvey et al. 
2002). This complex mutation with a deletion and a LINE insertion results in an 
in-frame deletion in the calpain 3 interacting N2A domain (Garvey et al. 2002). 
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Mutant molecules are expressed in two splice isoforms, a major 249 bp deleted 
isoform and a minor isoform with a LINE insertion (Garvey et al. 2002). A 
decrease of calpain 3 in the muscle of the MDM mouse was confirmed but the 
decrease was in the range of 50-60% compared to almost total loss observed by 
us. This may reflect different muscle groups analysed or different ages of the 
mice. However, calpain 3 deficiency does not explain the observed phenotype 
alone because mice with targeted calpain 3 mutation have a less severe 
phenotype than the MDM mice (Richard et al. 2000). This is also the case with 
the TMDFin homozygous patients with small amounts of calpain 3 left in their 
muscles and phenotype as severe as LGMD2A. There are no studies on the 
phenotype of the MDM heterozygote mice. The heterozygotes having a 
myopathy restricted to one muscle group, comparable to human TMD, may have 
gone unnoticed. 
 
General discussion on the molecular pathogenesis in titinopathies  
 
The gigantic titin molecules have multiple functions in muscle cells. They 
provide a filament system extending the length of the myofibrils and contribute 
to sarcomere assembly and probably determine the thick filament length. Titin 
molecules function as elastic springs that keep contractile elements in place. 
Further, titin has a kinase domain and may be involved in the signalling 
regulating muscle contraction and sarcomere protein turnover. Thus, mutations 
in different titin domains are likely to cause varying phenotypes. M-line 
mutations cause the skeletal muscle phenotype as shown by the present study 
while there are several titin mutations observed that cause cardiomyopathy 
(fig.18).  
 
The TMDFin mutation changed four amino acids within the conserved 
hydrophobic core domain of the M10 Ig-domain of M-line titin. One of the four 
amino acids, the tryptophan, is mutated into charged lysine. The tryptophan 
residue is generally conserved in all titin Ig-repeats and is known to be crucially 
important for stabilization of the hydrophobic core of the Ig β-barrel fold 
(Improta et al. 1996). The TMDFra mutation at position 293,357 changed leucine 
to proline. Both amino acids are neutral hydrophobic. Since proline differs from 
leucine because of its circular structure, it may introduce a kink and cause 
significant conformational change in the M-line titin structure. The TMDBel 
mutation may have similar effects as a non-polar hydrophobic isoleucine is 
changed to a polar uncharged asparagine. The mutant titin molecules are  
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Figure 18. A schematic representation of the titin molecule with arrows indicating the 
reported titin mutations resulting in human and comparable animal phenotypes. 
(Satoh et al. 1999, Gerull et al. 2002, Itoh-Satoh et al. 2002, Xu et al. 2002, Garvey et 
al. 2002, van den Bergh et al. 2003, III).
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
incorporated into the sarcomeres since immunohistochemistry indicates the 
presence of titin even in the homozygous patients. The loss of epitope 
recognition by the M-line M8/M9 antibody and the normal labelling of TMDFin 
homozygous patient muscle with the antibody A169/A170, together with the 
normal myomesin labelling, indicate that the titin structure may be 
conformationally disrupted distal to the M4 Ig-domain binding to myomesin. 
Alternatively, mutated proteins are C-terminally truncated. However, the 
mutated part of titin is located within the periphery of the M-line lattice and M-
line ultrastructure is preserved in the patient muscle. Interestingly, several 
molecules implied in myofibrillar signalling are associated with M-line titin. 
These include calpain3, MURF-1 and obscurin (Sorimachi et al. 1995, Bodine et 
al. 2001, Centner et al. 2001, Young et al. 2001). Functional evidence for the 
importance of M-line titin comes from knock out mice with selective deletion of 
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the kinase region of M-line ttn (Gotthard et al. 2003). The knock out mice are 
not viable. When M-line excision is introduced in late embryonic development, 
the mice have a progressive myopathy leading to an early death. Ultrastructural 
analysis suggested that the mutant titin molecules are incorporated into the 
sarcomere, disassembly and disruption of the sarcomere structure follows. 
 
Calpain 3 binding to N2A and M-line titin has been characterized (Sorimachi et 
al. 1995). It has been suggested that binding to titin prevents autolysis and 
degradation of calpain 3 in muscle, thus regulating the amount of calpain 3. 
Binding affinity and the binding site in calpain 3 are different in the N2A region 
and M-line (Sorimachi et al. 1995). Our results suggest that both M-line titin and 
N2A mutations could lead to a secondary calpain 3 deficiency in homozygous 
form. Calpain 3 amounts varied in TMDFin heterozygotes. The wild-type titin 
may still trap and bind some amount of calpain 3 stabilizing and protecting it 
from degradation. However, one functional allele may not be sufficient for all 
the binding capacity needed (haploinsufficiency) or mutated proteins may 
disrupt the complex structure of the M-line and wild-type protein interactions 
are blocked to some extent (dominant negative effect). The N2A domain is 
expressed in both skeletal and cardiac muscle but cardiomyocytes express an 
alternative N2B isoforms as well. Mex6 is expressed in both skeletal and heart 
muscle. On the other hand, calpain3 is not expressed in the mature heart muscle. 
The fact that TMD/LGMD2J patients have no cardiac phenotype further 
supports the pathogenetic significance of a defective titin-calpain3 interaction. A 
variable proportion of Mex5+ and Mex5- isoforms may have an effect on the 
selective muscle involvement seen in TMD. However, mice with targeted 
calpain 3 mutation have a less severe phenotype than the MDM mice (Richard et 
al. 2000) and the phenotype of TMDFin homozygous patient with small amounts 
of calpain 3 left in their muscles is as severe as LGMD2A. Thus, robust calpain 
3 binding and protection from autolysis does not solely explain the observed 
phenotypes. It could be that titin or other titin-associated proteins regulate 
calpain3 activity in a more delicate manner and these unknown molecular 
mechanisms are disrupted by TMD and MDM mutations. Yet other titin-
associated proteins in myofibrillar signalling could be involved in the 
pathogenesis of TMD/LGMD2J and MDM.  
 
The identification of the mutations causing LODM and the late-onset autosomal 
dominant myopathy with proximal muscle weakness and early respiratory 
failure is pending. Meanwhile, several mutations in TTN have been associated 
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with dilated cardiomyopathy (DCM) characterized by ventricular dilatation, 
systolic dysfunction and congestive heart failure. A two bp insertion in A-band 
titin results in a frame shift and expression of a 1.14 MD truncated titin with the 
full-length titin (Gerull et al. 2002). The truncated protein is suggested to result 
from cleavage by insufficiently bound calpain 3 (Gerull et al. 2002). Another 
mutation converts a conserved tryptophan to arginine in Z-disc titin and the 
mutation was predicted to disrupt the β-sandwich structure of the Ig-domain Z4 
(Gerull et al. 2002). Residue changes in Z-disc titin Ig-domain Z1 and Z-repeat 
7 were observed to decrease binding affinities to telethonin and α-actinin 
respectively in yeast two-hybrid studies (Itoh-Satoh et al. 2002). Finally, two 
changes in the cardiac specific N2B domain were discovered, one resulting in a 
premature stop-codon and one missense mutation (Itoh-Satoh et al. 2002). Only 
one patient with hypertrophic cardiomyopathy (HCM) has been reported to have 
a conserved residue replacement from arginine to leucine in Z-repeat 7 (Satoh et 
al. 1999). A mutation construct showed increased α-actinin binding affinity in a 
yeast two-hybrid assay (Satoh et al. 1999). All the human DCM and HCM 
mutations are observed in the heterozygous form. The missense mutations in the 
Z-disc region could exert a dominant negative effect on the assembly of the 
sarcomere structure. On the other hand, Z-disc mutated domains are also 
expressed in skeletal muscle, and the reported patients have no skeletal muscle 
phenotype. Disruption of cardiac specific signalling pathways i.e. responding to 
mechanical load could be one possible explanation. Cardiac specific N2B region 
mutations are skipped in splicing of skeletal isoforms while the N2B domain and 
its modification have unique regulatory roles on the elastic and contractile 
properties of the cardiac muscle (Linke et al. 2002, Kulke et al. 2001, Yamasaki 
et al. 2002, Neagoe et al. 2002, Golenhofen et al. 2002). The Pik mutant 
zebrafish presents a phenotype resembling human DCM. Recessive nonsense 
mutation in the cardiac expressed titin N2B domain has no effect on heart 
muscle development but causes systolic dysfunction leading to heart failure (Xu 
et al. 2002). 
 
Intensive research on the characteristics of titin and the phenotypes associated 
with TTN mutations have resulted in many discoveries. Yet, each question 
answered generates a dozen new ones. Titin seems to have more versatile 
functions in muscle cell than had been predicted. It will be a challenge to dissect 
the pathogenetic cascades involved in the titinopathies.  
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A new distal myopathy (MPD3) 
 
Clinical characterization (IV) 
 
Patients presenting with a distal myopathy that is distinct from the described 
phenotypes emerged during the TMD study. This large family with seven 
patients at the time (5 men and 2 women) in four generations was studied. One 
of the patients had died of cardiac problems at 84 years of age. Clinical data 
were reported by his daughter and obtained from his medical records. None of 
the patients had any symptoms or signs of muscle disease before the age of 30 
years. The age at onset ranged from 32 to 45 years. The first symptoms for 
referral were clumsiness with the hands of three patients and stumbling in four 
patients. The interval between the first and the second localization of muscle 
involvement was two to three years. At referral, all patients had a steppage gait. 
To compensate ankle dorsiflexion weakness, patients used excessive knee and 
hip flexion during the swing phase. All the patients were unable to walk on their 
heels and walking on tiptoe was impossible in the three severely affected 
patients.  
 
Muscle weakness in the lower limbs involved mainly the muscles of the anterior 
compartment of the lower legs (i.e. tibialis anterior, extensor digitorum brevis, 
extensor digitorum longus and peroneus muscles). The calf muscles were 
involved in three severely affected patients and there was moderate to severe hip 
abduction weakness. In the upper limbs, wasting and weakness of the hand 
muscles were observed with claw-like hands (fig. 19). Wasting or weakness in 
all the intrinsic muscles, wrist extensors and upper arm muscles was observed 
with the progression of the disease. In the lower limbs, the disease spread to 
other proximal muscles only in the late stages. Asymmetry of muscle 
involvement was present in all patients. The progression of the disease was 
slow, and the oldest patient of the family became wheelchair-bound at the age of 
75 years. Mild contractures were present about five to eight years after disease 
onset and involved mainly the finger, elbow, and wrist joints. None of the 
patients showed intellectual deficit, heart or respiratory problems.  
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Figure 19. Patient III-5 at the age of 50 
years. (A) The patient shows elbow and 
wrist contractures bilaterally. There is 
wasting of the infraspinatus, 
subscapularis, serratus anterior, triceps 
and right calf muscles. (B) Claw-hand 
appearance and wasting of the extensor 
digitorum longus. (D) The right tibial 
anterior muscle is severely wasted. In an 
attempt at ankle dorsiflexion, the patient 
shows severe weakness of the right ankle 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
EMG revealed myopathic findings consisting of a low amplitude pattern during 
voluntary effort and short duration low voltage polyphasic motor unit action 
potentials. Fibrillation and complex repetitive discharges were also recorded in 
severely affected muscles. No myotonic discharges were detected. Motor and 
sensory nerve conduction velocities were normal. Serum CK levels were normal 
or slightly elevated. Fatty degeneration of the anterior tibial and the hip 
abductors muscles by muscle imaging was shown in all patients and of the calf 
muscles in four patients (fig. 20). Muscle biopsy showed severe myopathic-
dystrophic changes. There was endomysial fibrosis and some fatty replacement. 
Fibre size variation was strongly increased and abundant rimmed vacuoles with 
some eosinophilic cytoplasmic inclusion bodies could be seen (fig. 21). Many 
and moderate 
weakness on the left 
side, while extensor 
digitorum brevis is 
bilaterally atrophic.
(E) Severe bilateral 
wasting of the thenar 
and hypothenar 
muscles. Mild finger 
contractures. (F) 
Severe wasting of the 
intrinsic muscles of 
the hands. Weakness 
of finger extensors is 
prominent on the 
right side. 
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Figure 20. Muscle CT scans 
from Patient III-5. Fatty 
replacement of both tensor 
fascia lata (1) and gluteus 
medium muscles (2). The 
thigh section shows only mild 
involvement of the long head 
of the biceps femoris (3) and 
the semimembranosus 
muscles (4). In the lower legs, 
the involvement is 
asymmetric, with severe fatty 
replacement of the right tibial 
anterior muscle (5) and mild 
fatty replacement of the 
extensor digitorum longus 
muscle (6). There is severe 
fatty replacement of the right 
and less of the left 
gastrocnemius muscle (7). 
atrophic fibres were angular and this was occasionally found in small groups. 
Occasional fibres and rimmed vacuoles were SMI-31-immunoreactive. In one of 
the biopsies, some scattered T-lymphocytes were identified. Electron 
microscopy revealed autophagic vacuoles. Immunocytochemistry showed 
normal label patterns of all the membrane proteins analysed. Western blotting 
revealed normal amounts of all proteins apart from the 94 kD and 30 kD calpain 
3 bands which were substantially reduced, while the bands at ~60 kD were 
increased. This was interpreted as protein degradation, rather than a specific 
feature of the myopathy. 
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Figure 21. Muscle biopsy from Patient III-5 obtained from the tibial anterior muscle. 
Severe myopathic-dystrophic pathologic changes can be observed: fibrosis, fatty 
change, huge fibre size variation, rimmed vacuoles (arrowheads), and eosinophilic 
cytoplasmic inclusion bodies (arrow). Some fibres show strong SMI-31-
immunoreactivity (c, arrowheads). Original magnifications and stainings: x160 (a 
through c), x400 (d); haematoxylin-eosin (a), van Gieson (b), SMI-31 
immunoperoxidase (c, Sternberger Monoclonals Inc., Baltimore, MD), and toluidine
blue (d, plastic section). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
During the following linkage study, the material was expanded with assessment 
of four additional family members. Two of these individuals were affected. 
Patient IV-11 was diagnosed after clinical examination showing early atrophy of 
the thenar and hypothenar muscles with overall thin muscle bulks. His muscle 
CT scans showed early minor lesions in the lower leg muscles. This patient also 
shows that the age of onset is before the age of 30, at least in males. Patient II-
10, the elderly sister of the proband’s mother, was not available for further 
clinical examinations. According to her medical records, she had walking 
difficulties at the age of 50 and used a cane for walking. Weakness of lower 
limb muscles was noted as the cause for her early retirement. 
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Figure 22. Pedigree of the MPD3 family. The index case is III-3. Samples from 
persons marked with a star were used in genome wide scan. Samples from II-9, II-10, 
IV-10 and IV-11 were included for the fine mapping studies.
Linkage studies (IV, V) 
 
The disease appeared in consecutive generations and in both sexes, suggesting 
an autosomal dominant pattern of inheritance (fig. 22). Markers were genotyped 
for WDM and TMD loci on chromosome 2 to test whether this family 
represented a variant phenotype. Haplotype studies in our patients showed no 
WDM- or TMD-specific founder haplotypes and segregation analyses clearly 
excluded linkage to both loci. A genome wide scan was performed with six 
patients and three healthy family members (fig. 22). Markers on seven regions 
(1q, 8p-q, 9p-q, 10q, 12q, 14q, and 20q)  generated two-point LOD scores >1. 
Subsequently, two additional patients were included in the study and a dense set 
of markers was genotyped for these loci. Inconsistent segregation of the 
haplotypes with the affection status and multipoint calculations suggested 
exclusion of linkage for 1q, 9p-q, 10q, 14q and 20q. Pairwise LOD scores for 
the two remaining loci on chromosomes 8 and 12 were remarkably similar (table 
7). The highest LOD score values for chromosome 8 were 2.92 and 2.94 with 
markers D8S136 and D8S1820, respectively and for chromosome 12 2.94 and 
2.92 with markers D12S375 and D12S1670, at zero recombination fraction. 
Multipoint LOD scores were calculated using the markers listed in table 7. 
Maximum multipoint LOD scores of 3.01 were observed for both loci (fig. 23). 
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Table 7. Pairwise LOD scores between the MPD3 locus and markers on 
chromosomes 8p21-q11 and 12q13-q22.
 
 
 
 
  Θ  =     
M a r k e r s      0 . 0 0 .01 0 . 0 5 0 . 1 0 . 2 0 . 3 0 .4 
D8S1106 -  ∞ 0 .96 1 .46 1.51 1.26 0 . 8 7 0.43 
D8S1731 -  ∞ -0.86 -0.15 0.12 0.32 0 . 3 2 0.21 
D8S1145 1.14 1 .11 0 .99 0.83 0.51 0 . 2 1 0.02 
D8S282 0.90 0 .89 0 .82 0.73 0.54 0 . 3 6 0.18 
D8S136 2.92 2 .87 2 .66 2.39 1.79 1 . 1 4 0.50 
D8S1786 2.71 2 .66 2 .46 2.21 1.65 1 . 0 5 0.45 
D8S382 2.19 2 .15 1 .99 1.78 1.33 0 . 8 4 0.38 
D8S1839 0.39 0 .38 0 .34 0.29 0.18 0 . 0 9 0.02 
D8S1820 2.94 2 .89 2 .67 2.40 1.81 1 . 1 6 0.52 
D8S1477 2.16 2 .13 1 .97 1.77 1.33 0 . 8 4 0.35 
D8S505 1.81 1 .78 1 .65 1.49 1.15 0 . 8 0 0.41 
D8S531 -  ∞ 0 .89 1 .40 1.45 1.20 0 . 7 9 0.33 
D8S1110 -  ∞ 0 .10 0 .66 0.77 0.68 0 . 4 4 0.17 
        
D12S1618 -  ∞ -0.09 0 .48 0.60 0.53 0 . 3 1 0.09 
D12S1586 -  ∞ 0 .96 1 .46 1.51 1.25 0 . 8 3 0.35 
D12S355 2.57 2 .52 2 .32 2.06 1.49 0 . 9 0 0.35 
D12S83 1.43 1 .41 1 .33 1.23 1.00 0 . 7 2 0.39 
D12S1686 2.05 2 .02 1 .86 1.65 1.20 0 . 7 3 0.28 
D12S1294 2.26 2 .22 2 .09 1.91 1.49 1 . 0 1 0.48 
D12S375 2.94 2 .88 2 .67 2.39 1.78 1 . 1 2 0.48 
D12S1052 1.20 1 .18 1 .09 0.98 0.75 0 . 5 0 0.25 
D12S1660 2.18 2 .14 1 .97 1.74 1.25 0 . 7 3 0.27 
D12S326 2.25 2 .20 2 .03 1.80 1.32 0 . 8 2 0.35 
D12S1708 1.65 1 .62 1 .50 1.35 1.04 0 . 7 1 0.37 
D12S1670 2.92 2 .87 2 .66 2.38 1.79 1 . 1 4 0.50 
D12S1064 2.11 2 .07 1 .91 1.70 1.24 0 . 7 6 0.29 
D12S351 1.51 1 .48 1 .39 1.28 1.02 0 . 7 3 0.40 
D12S327 -  ∞ 0 .96 1 .46 1.51 1.26 0 . 8 6 0.42 
D12S346 -  ∞ 0 .37 0 .93 1.05 0.96 0 . 7 2 0.40 
 74
Figure 23. Multipoint linkage analysis of the MPD3 locus, against a fixed set of 
markers on chromosome 8 and chromosome 12. Horizontal axis indicates 
distance in centiMorgans (cM).
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Further, a specific haplotype segregated with the disease on both loci. The 
obligatory recombinations on chromosome 8 were observed for markers 
D8S1731 and D8S531 separated by 34.5 cM. On chromosome 12 
recombinations were observed with markers D12S1586 and D12S327 flanking a 
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28.6 cM region. Simulation analysis with 1000 replicates predicted the average 
LOD score for linkage to be 1.92 and the maximum LOD score to be 3.01 for 
this particular family. Simulation analysis for unlinked markers predicted a LOD 
score over two in 0.4 percent and over three in 0.1 percent of the simulated 
markers making the observed linkage evidence at this significance level for the 
two loci unlikely. 
 
Both potentially linked loci are wide. The genomic sequence of the chromosome 
8 region is about 34 Mb including 349 known or predicted genes and the 
chromosome 12 region is about 41 Mb long including 433 known or predicted 
genes (International Human Genome Sequencing Consortium 2001). The genes 
expressed specifically in skeletal muscle were explored on these regions. The 
chromosome 12q MLC1SA gene encodes a myosin light chain 1 slow-twitch 
muscle isoform A, which is expressed in nonmuscle tissue as well as slow-
twitch skeletal muscles (Hailstones and Gunning 1990). The coding region, 
consisting of eight exons, was sequenced but no differences were identified 
between DNA samples from affected and healthy individuals or the sequence in 
the databases. The Ankyrin 1 gene (ANK1) on chromosome 8p, has skeletal 
muscle specific small splice variants, which are associated with sarcoplasmic 
reticulum and interact with titin and obscurin (Gallagher and Forget 1998, Zhou 
et al. 1997, Bagnato et al. 2003, Kontrogianni-Konstantopoulos et al. 2003, 
Kontrogianni-Konstantopoulos and Bloch 2003). These muscle specific 
isoforms have their own promoter and an alternative first exon followed by four 
commonly expressed exons. Again, no sequence variations were observed in the 
coding region. Three one basepair changes were detected in introns. All of them 
were concluded to represent polymorphisms, since they were also identified in 
the DNA samples of the healthy family members. Selfevidently, variants of the 
non-coding regions of these genes might still be causative for the disease, 
although for a dominant disease a mutation affecting the protein structure would 
represent the most plausible molecular defect. 
 
The distinction of the new distal myopathy, MPD3, from the other distal 
myopathies is based on the differences in clinical findings together with genetic 
exclusion of the known distal myopathy loci. The family material available was 
thought to be sufficiently informative for successful locus identification. 
However, an extensive genome wide scan showed linkage to two separate loci, 
8p22-q11 and 12q13-q22, with the multipoint LOD score of 3.01 for both loci. 
Statistical and haplotype analyses could not rule out one or the other of these 
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loci. Further, a LOD score of 3 has been acknowledged as a significant evidence 
for linkage in monogenic disorder (Conneally et al. 1985). This study shows that 
even in cases with a seemingly large enough family material, the assignment of 
linkage may prove to be a difficult task and even well established statistical 
analysis may show significant results for more than one locus.  
 
At present there are no additional family members available for the study, and 
ascertainment of other families or patients that would represent the same 
phenotype has not been successful so far. It may be beneficial to genotype the 
chromosome 8 and 12 markers in patients with unclassified distal myopathy, as 
they may share the same founder haplotype. In particular, this is appropriate for 
patients that are excluded to have the TMDFin mutation in titin or the specific 
founder haplotype of WDM.  
 
There are several reports of autosomal dominant distal myopathy families 
without linkage determination (Sumner et al. 1971, Penisson-Besnier et al. 1998, 
Felice et al. 1999, Chinnery et al. 2001). Patients from the family reported by 
Felice et al. developed weakness of the anterior compartment of their lower legs 
followed by progressive distal upper limb and proximal leg muscle weakness. 
The muscle affection pattern resembles MPD3 but the age of onset is earlier and 
the muscle pathology is milder without rimmed vacuoles. Likewise, the disorder 
in the family reported  by Sumner et al. bears some similarities, but the disease 
showed a more severe course. Despite these clinical differences the 8p22-q11 
and 12q13-q22 loci could be tested for linkage in these families. For example, 
there is a marked clinical variation in the aforementioned chromosome 2q31 
linked phenotypes (TMD, LODM, autosomal dominant myopathy with proximal 
muscle weakness and early respiratory failure, and cardiomyopathy).  
 
Identification of the MPD3 causing gene will be difficult without a definitely 
linked locus and a narrow critical region. The positional candidate gene 
approach was applied in this study, so far without success. Two genes are 
known to cause dominant distal myopathies: titin and cardiac beta-myosin 
(MYH7). In the recessively inherited telethoninopathy (LGMD2G) the initial 
weakness and atrophy may sometimes be distal and muscle biopsy shows 
rimmed vacuoles as well. Thus, sarcomeric proteins represent good candidates 
for causing distal muscle degeneration. Discoveries concerning the pathogenetic 
pathways involved in the other (distal) myopathies may provide new candidate 
genes to be screened for the MPD3 causing mutation in the future. 
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CONCLUDING REMARKS  
 
The first section of this thesis presents the identification of the defective gene 
and the mutations causing tibial muscular dystrophy (TMD) by a positional 
candidate approach. The second section presents the characterization and 
linkage studies for a novel distal myopathy (MPD3).  
 
The TMD locus was assigned to chromosome 2q31 in Finnish families and the 
genetic homogeneity was shown by linkage to the same locus in a French 
family. Further, a similar late-onset distal myopathy (LODM) phenotype in an 
American family was linked to chromosome 2q31. Sequencing of the giant TTN 
gene identified TMD causing mutations in the Mex6 exon, which encodes Ig-
domain M10 in the ultimate C-terminus of titin. M10 is located in the M-line 
region of the sarcomere. The identified mutations possibly disrupt the Ig-domain 
structure. Interestingly, three patients with a severe limb-girdle muscular 
dystrophy (LGMD2J) phenotype were homozygous for the TMDFin mutation.  
 
Immunohistochemical studies indicated incorporation of the mutant titin 
molecules to the sarcomere, but an altered structure of titin C-terminus located 
in the periphery of the M-line. Further, the amount of titin ligand calpain 3 
varied in the muscle samples from heterozygous TMD patients and there was a 
severe loss of calpain 3 in homozygous patient. Myonuclear apoptosis and 
perturbation of the IκBα/NF-κB pathway that are similar to the primary 
calpainopathy (LGMD2A) were observed as well. However, the animal studies 
of calpain 3 deficient mice and the spontaneous titin mutant MDM-mouse 
suggest that the TMD phenotype might not result from the calpain 3 deficiency 
alone. The contribution of titin to the complex M-line structure and its role in 
signalling and regulatory pathways for sarcomeric protein turnover have begun 
to emerge. This includes interaction with recently discovered M-line molecules, 
such as MURFs and obscurin. The goal for the future will be to clarify the 
details of how the mutations affect titin interaction with calpain 3 and the other 
ligands. This may shed light on the molecular mechanisms regulated by the M-
line components that are involved in the muscle degeneration in TMD and other 
myopathies. 
 
In the second part of this study the MPD3 phenotype was characterized in a 
Finnish family. Molecular genetic studies excluded linkage to the known distal 
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myopathy loci. Unexpectedly, a genome wide scan provided significant 
evidence for linkage to two chromosomal regions, 8p22-q11 and 12q13-q22, and 
it was impossible to make any distinction between them. Unclassified distal 
myopathy patients and unlinked families reported by others may be tested for 
these loci in order to confirm the locus assignment. Identification of the MPD3 
disease gene and mutation will be intriguing, particularly finding the 
pathogenetic pathways involved and the possible connections to TMD and the 
other muscular dystrophies.  
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